

Kaj Blennow

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3300767/kaj-blennow-publications-by-year.pdf>

Version: 2023-09-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,304
papers

77,808
citations

130
h-index

251
g-index

1,519
ext. papers

99,548
ext. citations

6.2
avg, IF

8.21
L-index

#	Paper	IF	Citations
1304	Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults.. <i>Annals of Neurology</i> , 2022 ,	9.4	3
1303	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization.. <i>Pain Reports</i> , 2022 , 7, e988	3.5	1
1302	Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	1
1301	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	2
1300	Crosswalk study on blood collection-tube types for Alzheimer's disease biomarkers.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022 , 14, e12266	5.2	0
1299	Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients.. <i>Fluids and Barriers of the CNS</i> , 2022 , 19, 11	7	3
1298	Amyloid processing in COVID-19 associated neurological syndromes.. <i>Journal of Neurochemistry</i> , 2022 ,	6	2
1297	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics.. <i>Frontiers in Neurology</i> , 2022 , 13, 826423	4.1	0
1296	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease.. <i>EBioMedicine</i> , 2022 , 76, 103836	8.8	4
1295	The accuracy and robustness of plasma biomarker models for amyloid PET positivity.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 26	9	4
1294	Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.. <i>British Journal of Anaesthesia</i> , 2022 ,	5.4	1
1293	Comparing tau status determined via plasma pTau181, pTau231 and [F]MK6240 tau-PET.. <i>EBioMedicine</i> , 2022 , 76, 103837	8.8	1
1292	Quantification of the trans-synaptic partners neurexin-neuroigin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry.. <i>EBioMedicine</i> , 2022 , 75, 103793	8.8	0
1291	Alzheimer's disease related biomarkers in bipolar disorder - A longitudinal one-year case-control study. <i>Journal of Affective Disorders</i> , 2022 , 297, 623-633	6.6	1
1290	Cerebrospinal fluid neurogranin in Alzheimer's disease studies: are immunoassay results interchangeable?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022 , 60, e13-e17	5.9	
1289	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. <i>Aids</i> , 2022 , 36, 75-82	3.5	2
1288	Comparing the effect of xenon and sevoflurane anesthesia on postoperative neural injury biomarkers: a randomized controlled trial. <i>Medical Gas Research</i> , 2022 , 12, 10-17	2.2	2

1287	Plasma and CSF NFL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022 , 14, e12295	5.2	0
1286	Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein-β in patients with subcortical small-vessel disease.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022 , 14, e12296	5.2	1
1285	Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus.. <i>Fluids and Barriers of the CNS</i> , 2022 , 19, 15	7	0
1284	Cerebral Biomarkers and Blood-Brain Barrier Integrity in Preeclampsia.. <i>Cells</i> , 2022 , 11,	7.9	1
1283	CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	3
1282	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles.. <i>Journal of Neural Transmission</i> , 2022 , 129, 231	4.3	0
1281	Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change.. <i>Acta Neuropathologica</i> , 2022 , 143, 487	14.3	6
1280	Exploring common genetic contributors to neuroprotection from amyloid pathology.. <i>Brain Communications</i> , 2022 , 4, fcac066	4.5	1
1279	Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study.. <i>Brain Communications</i> , 2022 , 4, fcac040	4.5	0
1278	Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest.. <i>Brain Injury</i> , 2022 , 1-10	2.1	0
1277	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.. <i>Lancet Neurology</i> , 2022 , 21, 246-257	24.1	16
1276	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 27	19	1
1275	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 46	9	1
1274	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 840651	5.3	0
1273	Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease.. <i>Frontiers in Neurology</i> , 2022 , 13, 839307	4.1	0
1272	Development of Fluid Biomarkers for Alzheimer's Disease 2022 , 361-374		
1271	Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease.. <i>Translational Psychiatry</i> , 2022 , 12, 151	8.6	1
1270	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.. <i>Lancet Neurology</i> , 2022 , 21, 329-341	24.1	4

1269	Decreased Electroencephalography Global Field Synchronization in Slow-Frequency Bands Characterizes Synaptic Dysfunction in Amnesic Subtypes of Mild Cognitive Impairment.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 755454	5.3	0
1268	Effect of Race on Prediction of Brain Amyloidosis by Plasma A β 2/A β 0, Phosphorylated Tau, and Neurofilament Ligh.. <i>Neurology</i> , 2022 ,	6.5	4
1267	Statistical Parametric Mapping in Amyloid Positron Emission Tomography.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 849932	5.3	0
1266	Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults.. <i>Neurobiology of Aging</i> , 2022 , 116, 80-91	5.6	2
1265	Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients.. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022 , 1-11	2.6	0
1264	Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 65	9	2
1263	Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 63, 103846	4	
1262	Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer's disease biomarkers.. <i>Clinical Proteomics</i> , 2022 , 19, 13	5	1
1261	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.. <i>Nature Reviews Neurology</i> , 2022 ,	15	4
1260	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022 , 17, e0267298	3.7	1
1259	Cerebrospinal Fluid Biomarkers, Brain Structural and Cognitive Performances Between Normotensive and Hypertensive Controlled, Uncontrolled and Untreated 70-Year-Old Adults.. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 777475	5.3	0
1258	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021 , 17,	1.2	3
1257	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 198	9	14
1256	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021 , 78, 1471-1483	17.2	18
1255	Truncating tau reveals different pathophysiological actions of oligomers in single neurons. <i>Communications Biology</i> , 2021 , 4, 1265	6.7	0
1254	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives.. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021 , 48674211058684	2.6	1
1253	Prodromal frontotemporal dementia: clinical features and predictors of progression. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 188	9	0
1252	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2021 ,	17.2	4

1251	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2021 ,	13.5	17
1250	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 ,	5.9	2
1249	Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. <i>Journal of Neurology</i> , 2021 , 1	5.5	2
1248	Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. <i>Scientific Reports</i> , 2021 , 11, 22128	4.9	3
1247	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	12
1246	Association between serum urate and CSF markers of Alzheimer's disease pathology in a population-based sample of 70-year-olds.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12241	5.2	0
1245	The Brain-Nose Interface: A Potential Cerebrospinal Fluid Clearance Site in Humans.. <i>Frontiers in Physiology</i> , 2021 , 12, 769948	4.6	3
1244	The global Alzheimer's Association round robin study on plasma amyloid [methods. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12242	5.2	2
1243	Serum Neurofilament Light is elevated in COVID-19 Positive Adults in the ICU and is associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness. <i>Cardiology and Cardiovascular Medicine</i> , 2021 , 5, 551-565	1.3	1
1242	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 169	9	10
1241	Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight. <i>JAMA Neurology</i> , 2021 , 78, 1525-1527	17.2	6
1240	Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. <i>Scientific Reports</i> , 2021 , 11, 20375	4.9	0
1239	Interactions between dietary patterns and genetic factors in relation to incident dementia among 70-year-olds. <i>European Journal of Nutrition</i> , 2021 , 1	5.2	1
1238	Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2021 , 18, 573-584	3	2
1237	Lower plasma total tau in adolescent psychosis: Involvement of the orbitofrontal cortex. <i>Journal of Psychiatric Research</i> , 2021 , 144, 255-261	5.2	0
1236	Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 175	7.3	8
1235	Axonal Injury Partially Mediates Associations Between Increased Left Ventricular Mass Index and White Matter Damage. <i>Stroke</i> , 2021 , STROKEAHA121034349	6.7	
1234	P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021 , 13, e15098	12	4

1233	Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. <i>Brain</i> , 2021 , 144, 434-449	11.2	21
1232	Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1131-1136	9.5	3
1231	Thirty years after anorexia nervosa onset, serum neurofilament light chain protein concentration indicates neuronal injury. <i>European Child and Adolescent Psychiatry</i> , 2021 , 30, 1907-1915	5.5	4
1230	Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. <i>Journal of Neurochemistry</i> , 2021 , 159, 389-402	6	7
1229	Cerebral amyloid- β load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021 , 17, 788-800	1.2	3
1228	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. <i>Alzheimer's and Dementia</i> , 2021 , 17, 801-812	1.2	7
1227	Proteomic blood profiling in mild, severe and critical COVID-19 patients. <i>Scientific Reports</i> , 2021 , 11, 6357-6369	4.9	25
1226	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2121-2139	8.8	18
1225	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1575-1582	1.2	12
1224	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1452-1464	1.2	4
1223	Negligible influence of moderate to severe hyperthermia on blood-brain barrier permeability and neuronal parenchymal integrity in healthy men. <i>Journal of Applied Physiology</i> , 2021 , 130, 792-800	3.7	2
1222	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 68	9	35
1221	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2140-2156	8.8	31
1220	Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers. <i>Translational Stroke Research</i> , 2021 , 1	7.8	3
1219	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	4
1218	Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. <i>Journal of Neurology</i> , 2021 , 268, 3574-3583	5.5	12
1217	Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 65	9	13
1216	Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 64	9	1

1215	Acute hyperglycaemia leads to altered frontal lobe brain activity and reduced working memory in type 2 diabetes. <i>PLoS ONE</i> , 2021 , 16, e0247753	3.7	2
1214	Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 54	9	2
1213	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 69	9	10
1212	Plasma amyloid- β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. <i>Brain</i> , 2021 , 144, 2964-2970	11.2	6
1211	Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy. <i>Journal of Neuroimmunology</i> , 2021 , 353, 577493	3.5	0
1210	No neurochemical evidence of neuronal injury or glial activation in children with Paediatric Acute-onset Neuropsychiatric Syndrome. An explorative pilot study. <i>World Journal of Biological Psychiatry</i> , 2021 , 22, 800-804	3.8	0
1209	Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 86	9	11
1208	TREM2 expression in the brain and biological fluids in prion diseases. <i>Acta Neuropathologica</i> , 2021 , 141, 841-859	14.3	5
1207	Synergistic Association between Plasma A β and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia. <i>ACS Chemical Neuroscience</i> , 2021 , 12, 1376-1383	5.7	2
1206	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1189-1204	1.2	9
1205	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021 , 3, fcab073	4.5	7
1204	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021 , 78, 396-406	17.2	41
1203	Analysis of Brain Injury Biomarker Neurofilament Light and Neurodevelopmental Outcomes and Retinopathy of Prematurity Among Preterm Infants. <i>JAMA Network Open</i> , 2021 , 4, e214138	10.4	4
1202	Postoperative troponin increases after noncardiac surgery are associated with raised neurofilament light: a prospective observational cohort study. <i>British Journal of Anaesthesia</i> , 2021 , 126, 791-798	5.4	5
1201	One-Year Prospective Study of Plasma Biomarkers From CNS in Patients With Mild Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2021 , 12, 643743	4.1	5
1200	Plasma neurofilament light chain levels predict improvement in late phase after stroke. <i>European Journal of Neurology</i> , 2021 , 28, 2218-2228	6	1
1199	Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 659898	5.3	3
1198	Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	3

1197	Characterization of monomeric and soluble aggregated A β in Down's syndrome and Alzheimer's disease brains. <i>Neuroscience Letters</i> , 2021 , 754, 135894	3.3	5
1196	Biomarkers of Cerebral Injury for Prediction of Postoperative Cognitive Dysfunction in Patients Undergoing Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021 ,	2.1	4
1195	Effects of amyloid pathology and the APOE ϵ allele on the association between cerebrospinal fluid A β 8 and A β 40 and brain morphology in cognitively normal 70-years-olds. <i>Neurobiology of Aging</i> , 2021 , 101, 1-12	5.6	0
1194	Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. <i>Journal of Affective Disorders</i> , 2021 , 286, 275-281	6.6	3
1193	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. <i>PLoS ONE</i> , 2021 , 16, e0250987	3.7	5
1192	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	6
1191	Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins: An In Vivo and Postmortem Study. <i>Neurology</i> , 2021 ,	6.5	2
1190	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021 , 27, 1034-1042	50.5	56
1189	Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus. <i>Fluids and Barriers of the CNS</i> , 2021 , 18, 23	7	3
1188	Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 667-677	4.3	0
1187	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1628-1640	1.2	4
1186	Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy. <i>PLoS ONE</i> , 2021 , 16, e0248980	3.7	4
1185	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. <i>Journal of Immunology</i> , 2021 ,	5.3	6
1184	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
1183	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , 2021 , 20, 484-496	24.1	86
1182	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1206-1214	5.5	10
1181	Following spatial A β aggregation dynamics in evolving Alzheimer's disease pathology by imaging stable isotope labeling kinetics. <i>Science Advances</i> , 2021 , 7,	14.3	3
1180	Cardiac troponin T is elevated and increases longitudinally in ALS patients. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021 , 1-8	3.6	1

1179	Clinical Utility of β Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 87, 826-833	3.1	1
1178	Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1456-1470	5.3	3
1177	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β ₂ /A β ₀ and p-tau. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	12
1176	Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis. <i>Aids</i> , 2021 , 35, 2129-2136	3.5	1
1175	Spitting image: can saliva biomarkers reflect Alzheimer's disease?. <i>EBioMedicine</i> , 2021 , 68, 103437	8.8	0
1174	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021 , 290, 583-601	10.8	15
1173	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021 , 12, 3400	17.4	51
1172	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021 , 3, fcb136	4.5	3
1171	Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. <i>Neurobiology of Aging</i> , 2021 , 102, 151-160	5.6	1
1170	CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB. <i>Movement Disorders</i> , 2021 , 36, 2595-2604	7	4
1169	Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. <i>Journal of Neurochemistry</i> , 2021 , 159, 234-257	6	0
1168	Cognitively unimpaired individuals with a low burden of A β pathology have a distinct CSF biomarker profile. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 134	9	4
1167	Circulating granulocyte colony-stimulating factor and functional outcome after ischemic stroke: an observational study. <i>Neurological Research</i> , 2021 , 43, 1013-1022	2.7	
1166	Circulating brain injury biomarkers increase after endoscopic surgery for pituitary tumors. <i>Journal of Clinical Neuroscience</i> , 2021 , 89, 113-121	2.2	1
1165	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021 , 13, e14398	12	8
1164	Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study. <i>Menopause</i> , 2021 , 28, 1099-1107	2.5	2
1163	Cohort Analysis of the Association of Delirium Severity with Cerebrospinal Fluid Amyloid-Tau-Neurodegeneration Pathologies. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021 ,	6.4	6
1162	Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. <i>Cells</i> , 2021 , 10,	7.9	5

1161	CSF Synuclein correlates with CSF neurogranin in late-life depression. <i>International Journal of Neuroscience</i> , 2021 , 131, 357-361	2	3
1160	Postanoxic electrographic status epilepticus and serum biomarkers of brain injury. <i>Resuscitation</i> , 2021 , 158, 253-257	4	3
1159	Determining Amyloid- β Positivity Using F-AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 247-252	8.9	20
1158	Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer's disease. <i>Sleep</i> , 2021 , 44,	1.1	3
1157	No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62). <i>Journal of Infectious Diseases</i> , 2021 , 223, 1928-1933	7	5
1156	Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. <i>European Journal of Neurology</i> , 2021 , 28, 587-594	6	4
1155	Association between cerebrospinal fluid biomarkers of neuronal injury or amyloidosis and cognitive decline after major surgery. <i>British Journal of Anaesthesia</i> , 2021 , 126, 467-476	5.4	1
1154	Molecular forms of neurogranin in cerebrospinal fluid. <i>Journal of Neurochemistry</i> , 2021 , 157, 816-833	6	3
1153	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021 , 17, 755-767	1.2	31
1152	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021 , 1, 114-123		34
1151	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 259-265	5.3	9
1150	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021 , 144, 325-339	11.2	42
1149	Untangling the association of amyloid- β and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021 , 144, 310-324	11.2	34
1148	ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2021 , 17, 822-830	1.2	9
1147	Association between plasma tau and postoperative delirium incidence and severity: a prospective observational study. <i>British Journal of Anaesthesia</i> , 2021 , 126, 458-466	5.4	18
1146	Associations between mean arterial pressure during cardiopulmonary bypass and biomarkers of cerebral injury in patients undergoing cardiac surgery: secondary results from a randomized controlled trial. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021 , 32, 229-235	1.8	5
1145	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 729-741	4.3	4
1144	An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. <i>Alzheimer's and Dementia</i> , 2021 , 17, 431-445	1.2	26

1143	Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury. <i>Clinica Chimica Acta</i> , 2021 , 512, 74-83	6.2	4
1142	Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. <i>European Journal of Neurology</i> , 2021 , 28, 974-981	6	6
1141	A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. <i>Acta Neuropathologica</i> , 2021 , 141, 217-233	14.3	12
1140	Proinflammatory protein signatures in cryptogenic and large artery atherosclerosis stroke. <i>Acta Neurologica Scandinavica</i> , 2021 , 143, 303-312	3.8	0
1139	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021 , 26, 429-442	15.1	70
1138	Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren's syndrome. <i>Journal of Neurology</i> , 2021 , 268, 1385-1394	5.5	6
1137	36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 , 17, 29-40	1.2	32
1136	Serum-neuroproteins, near-infrared spectroscopy, and cognitive outcome after beach-chair shoulder surgery: Observational cohort study analyses. <i>Acta Anaesthesiologica Scandinavica</i> , 2021 , 65, 26-33	1.9	0
1135	Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. <i>Intensive Care Medicine</i> , 2021 , 47, 39-48	14.5	38
1134	Association of Early β Amyloid Accumulation and Neuroinflammation Measured With [C]PBR28 in Elderly Individuals Without Dementia. <i>Neurology</i> , 2021 , 96, e1608-e1619	6.5	9
1133	A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021 , 76, 983-990	6.4	4
1132	Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 225-235	4.3	1
1131	Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12168	5.2	12
1130	Sex differences in CSF biomarkers for neurodegeneration and blood-brain barrier integrity. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12141	5.2	2
1129	Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre-analytical conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12145	5.2	7
1128	The relationship between white matter microstructure and self-perceived cognitive decline. <i>NeuroImage: Clinical</i> , 2021 , 32, 102794	5.3	0
1127	Measurement batch differences and between-batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12194	5.2	1
1126	Parkinson's disease with restless legs syndrome-an in vivo corneal confocal microscopy study. <i>Npj Parkinson's Disease</i> , 2021 , 7, 4	9.7	6

1125	Cerebrospinal fluid biomarkers of glial and axonal injury in cervical spondylotic myelopathy. <i>Journal of Neurosurgery: Spine</i> , 2021 , 34, 632-641	2.8	1
1124	Plasma metabolomics of presymptomatic PSEN1-H163Y mutation carriers: a pilot study. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 579-591	5.3	
1123	A Western-style dietary pattern is associated with cerebrospinal fluid biomarker levels for preclinical Alzheimer's disease-A population-based cross-sectional study among 70-year-olds. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12183	6	2
1122	Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. <i>European Journal of Neurology</i> , 2021 , 28, 3324-3331	6	31
1121	Head-to-head comparison of amplified plasmonic exosome A β 2 platform and single-molecule array immunoassay in a memory clinic cohort. <i>European Journal of Neurology</i> , 2021 , 28, 1479-1489	6	4
1120	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 17	9	11
1119	Plasma β secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021 , 17, 629-640	1.2	4
1118	Neuroigin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 19	7.3	8
1117	Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. <i>Molecular Neurodegeneration</i> , 2021 , 16, 10	19	35
1116	Detection of β amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. <i>Brain Communications</i> , 2021 , 3, fcb008	4.5	14
1115	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 38	9	4
1114	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 , 17, 813-821	1.2	4
1113	Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 1297-1305	4.3	8
1112	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021 , 141, 709-724	14.3	83
1111	Signs of neuroaxonal injury in preeclampsia-A case control study. <i>PLoS ONE</i> , 2021 , 16, e0246786	3.7	5
1110	Predicting neurological outcome after out-of-hospital cardiac arrest with cumulative information; development and internal validation of an artificial neural network algorithm. <i>Critical Care</i> , 2021 , 25, 83	10.8	8
1109	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 46	9	2
1108	Association of Depressive Symptoms With Postoperative Delirium and CSF Biomarkers for Alzheimer's Disease Among Hip Fracture Patients. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 1212-1221	6.5	2

1107	Plasma P-tau181 to A β 2 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1649-1662	1.2	12
1106	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021 ,	6.5	5
1105	Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 148, 96-98	11.5	18
1104	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021 , 12, 4304	17.4	11
1103	Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. <i>Brain</i> , 2021 ,	11.2	31
1102	Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial. <i>Arthritis Research and Therapy</i> , 2021 , 23, 189	5.7	0
1101	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021 , 17, 580-589	15	25
1100	Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. <i>Clinical Neurophysiology</i> , 2021 , 132, 1733-1740	4.3	40
1099	Amyloid- β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. <i>Neurobiology of Aging</i> , 2021 , 104, 24-31	5.6	2
1098	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021 , 9,	4.6	2
1097	Preclinical longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 271678X211035625	7.3	1
1096	Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211039104	5	1
1095	Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. <i>EBioMedicine</i> , 2021 , 70, 103512	8.8	23
1094	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021 , 27, 1592-1599	30.5	44
1093	Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021 , 83, 355-366	4.3	0
1092	Association of Apolipoprotein E e4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021 , 78, 937-947	17.2	11
1091	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 135	9	0
1090	Phenotyping Alzheimer's disease with blood tests. <i>Science</i> , 2021 , 373, 626-628	33.3	5

1089	Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage. <i>Scientific Reports</i> , 2021 , 11, 16950	4.9	0
1088	Blood Biomarkers for Alzheimer's Disease in Down Syndrome. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
1087	Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. <i>British Journal of Haematology</i> , 2021 ,	4.5	0
1086	The Amyloid- β Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	63
1085	Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. <i>Intensive Care Medicine</i> , 2021 , 47, 984-994	14.5	10
1084	Ultra-Early Differential Diagnosis of Acute Cerebral Ischemia and Hemorrhagic Stroke by Measuring the Prehospital Release Rate of GFAP. <i>Clinical Chemistry</i> , 2021 , 67, 1361-1372	5.5	1
1083	Head-to-Head Comparison of 8 Plasma Amyloid- β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurology</i> , 2021 , 78, 1375-1382	17.2	29
1082	Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	2
1081	The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 161	9	3
1080	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021 , 78, 1108-1117	17.2	25
1079	Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial-The OmegAD Study. <i>Journal of Alzheimer's Disease</i> , 2021 , 83, 1291-1301	4.3	1
1078	Association of deranged cerebrovascular reactivity with brain injury following cardiac arrest: a post-hoc analysis of the COMACARE trial. <i>Critical Care</i> , 2021 , 25, 350	10.8	0
1077	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2021 , 84, 119-128	4.3	1
1076	Amyloid pathology and synaptic loss in pathological aging. <i>Journal of Neurochemistry</i> , 2021 , 159, 258-276		0
1075	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. <i>Nature Genetics</i> , 2021 , 53, 1276-1282	36.3	40
1074	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , 2021 , 20, 739-752	24.1	43
1073	Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world investigation. <i>Journal of Neurochemistry</i> , 2021 , 159, 618-628	6	7
1072	Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. <i>EClinicalMedicine</i> , 2021 , 39, 101070	11.3	7

1071	Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 151	9	1
1070	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	11
1069	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1231-1241	5.5	14
1068	Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder. <i>Journal of Affective Disorders</i> , 2021 , 293, 429-434	6.6	1
1067	A genome-wide association study of plasma phosphorylated tau181. <i>Neurobiology of Aging</i> , 2021 , 106, 304.e1-304.e3	5.6	1
1066	Sulfatide in health and disease. The evaluation of sulfatide in cerebrospinal fluid as a possible biomarker for neurodegeneration. <i>Molecular and Cellular Neurosciences</i> , 2021 , 116, 103670	4.8	2
1065	Association of plasma A β 0/A β 2 ratio and brain A β accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021 , 107, 57-69	5.6	1
1064	Brain injury markers in new-onset seizures in adults: A pilot study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021 , 92, 62-67	3.2	2
1063	Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Environment International</i> , 2021 , 157, 106864	12.9	7
1062	Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients - A PET/MR study. <i>NeuroImage: Clinical</i> , 2021 , 30, 102665	5.3	5
1061	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1145-1156	1.2	48
1060	Polygenic risk scores for Alzheimer's disease are related to dementia risk in APOE e4 negatives. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12142	5.2	5
1059	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. <i>Translational Psychiatry</i> , 2021 , 11, 27	8.6	55
1058	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3019-e3026	11.6	50
1057	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. <i>Brain Communications</i> , 2021 , 3, fcab099	4.5	15
1056	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1365-1382	1.2	11
1055	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	3
1054	Structural Amyloid Plaque Polymorphism is Associated with Distinct Lipid Accumulations Revealed by Trapped Ion Mobility Mass Spectrometry Imaging (TIMS MSI). <i>Journal of Neurochemistry</i> , 2021 ,	6	4

1053	βSecretase modulators show selectivity for βSecretase-mediated amyloid precursor protein intramembrane processing.. <i>Journal of Cellular and Molecular Medicine</i> , 2021 ,	5.6	2
1052	Alzheimer's disease genetic risk variants show brain cell type-specific associations with protein levels in cerebrospinal fluid.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e049531	1.2	
1051	Plasma pTau isoform assessment across disease stages. <i>Alzheimer's and Dementia</i> , 2021 , 17,	1.2	1
1050	Diet and APOE as moderators of the relationship between trimethylamine N-oxide and biomarkers of Alzheimer's disease and glial activation.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e051827	1.2	1
1049	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer's disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e053030	1.2	
1048	A role for inflammaging in βsynuclein-associated breakdown of local sleep in the elderly.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e054208	1.2	
1047	Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e055011	1.2	
1046	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e055451	1.2	
1045	CSF Aβ2 and Aβ0 and their relation to brain soluble and insoluble Aβ in the 5xFAD mouse model of Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e055684	1.2	
1044	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 168	9	2
1043	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020 , 16, e036954	1.2	1
1042	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e037097	1.2	
1041	Plasma P-tau immunoassays, methodological aspects and clinical performance. <i>Alzheimer's and Dementia</i> , 2020 , 16, e037515	1.2	
1040	Phospho-tau217 and phospho-tau181 in plasma and CSF as biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e037520	1.2	1
1039	Plasma phospho-tau181 in over 400 cognitively healthy 69- to 71-year-olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study. <i>Alzheimer's and Dementia</i> , 2020 , 16, e037848	1.2	
1038	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. <i>Alzheimer's and Dementia</i> , 2020 , 16, e037912	1.2	
1037	Sex differences in CSF biomarkers for neurodegeneration and blood-brain barrier integrity. <i>Alzheimer's and Dementia</i> , 2020 , 16, e038588	1.2	
1036	Protective genetic variants in the MS4A gene cluster modulate microglial activity. <i>Alzheimer's and Dementia</i> , 2020 , 16, e039431	1.2	1

1035	Reduction of neurogranin immunostaining in the hippocampus of post-mortem brain of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040707	1.2	
1034	AD biomarker stability for stored CSF based on immunoassay results. <i>Alzheimer's and Dementia</i> , 2020, 16, e040747	1.2	
1033	Associations of dietary patterns and CSF biomarkers for Alzheimer's disease in a population-based sample of 70-year-olds. <i>Alzheimer's and Dementia</i> , 2020, 16, e040800	1.2	
1032	CSF 7-ketocholesterol is related to β amyloid and white matter microstructure in healthy adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e041015	1.2	
1031	Selective association of neurogranin gene expression with amyloid and tau pathology in the parahippocampal gyrus in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041053	1.2	
1030	An ultrasensitive immunoassay for detection of p-tau181 in blood. <i>Alzheimer's and Dementia</i> , 2020, 16, e041238	1.2	0
1029	Association of plasma YKL-40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020, 16, e041753	1.2	
1028	Characterization of monomeric and soluble aggregated A β in Down's syndrome and Alzheimer's disease brains. <i>Alzheimer's and Dementia</i> , 2020, 16, e042479	1.2	
1027	Research diagnostic criteria for Alzheimer's disease: Findings from the multinational LipiDiDiet Trial. <i>Alzheimer's and Dementia</i> , 2020, 16, e042530	1.2	
1026	A novel proteomics assay allows parallel quantitation of a panel of synaptic proteins in human cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2020, 16, e042578	1.2	
1025	Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e042955	1.2	
1024	Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer's disease from healthy controls. <i>Alzheimer's and Dementia</i> , 2020, 16, e043467	1.2	1
1023	The interaction of amyloid and tau on decreased cortical neurite density in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043979	1.2	
1022	CSF NFL levels and neuroimaging-derived neurite density index improve prediction of MCI and dementia clinical diagnosis within the Alzheimer's pathologic framework. <i>Alzheimer's and Dementia</i> , 2020, 16, e043987	1.2	0
1021	Elevated levels of synaptic protein GAP-43 associate with brain tauopathy, atrophy and cognition in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044098	1.2	
1020	Amyloid- β tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044444	1.2	
1019	Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. <i>Alzheimer's and Dementia</i> , 2020, 16, e044466	1.2	0
1018	Cerebrospinal fluid levels of SNAP-25 and SYT1 in Alzheimer's and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044515	1.2	0

1017	Genetically predicted telomere length and Alzheimer's disease endophenotypes: A Mendelian randomization study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044720	1.2	
1016	The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women. <i>Alzheimer's and Dementia</i> , 2020, 16, e044722	1.2	
1015	Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044733	1.2	
1014	Higher fronto-parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. <i>Alzheimer's and Dementia</i> , 2020, 16, e044780	1.2	
1013	Air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e044802	1.2	0
1012	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044808	1.2	
1011	APOE- ϵ shapes temporo-parietal network properties in middle-aged, cognitively unimpaired individuals: A graph theory analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045092	1.2	
1010	Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middle-aged adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045137	1.2	
1009	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. <i>Alzheimer's and Dementia</i> , 2020, 16, e045171	1.2	
1008	Incidence of subjective cognitive decline is associated with amyloid- β pathology, whereas stability relates to neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e045293	1.2	
1007	CSF phosphorylated tau-217 is increased in Alzheimer's and Creutzfeldt-Jakob diseases and correlates with amyloid pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, e045296	1.2	3
1006	Amyloid-positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. <i>Alzheimer's and Dementia</i> , 2020, 16, e045715	1.2	
1005	Impact of APOE- ϵ on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e045828	1.2	1
1004	DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045853	1.2	
1003	Levels of amyloid β in cerebrospinal fluid predicts cognition five years later: A population-based study of 70-year-olds. <i>Alzheimer's and Dementia</i> , 2020, 16, e045969	1.2	
1002	Multimodal genome-wide meta-analysis of brain amyloidosis reveals heterogeneity across CSF, PET, and pathological amyloid measures. <i>Alzheimer's and Dementia</i> , 2020, 16, e046009	1.2	
1001	Principal components from untargeted CSF metabolomics associated with tau. <i>Alzheimer's and Dementia</i> , 2020, 16, e046065	1.2	
1000	Baseline cerebrospinal fluid biomarkers of amyloidosis, phosphorylated tau, and total tau relate to greater longitudinal atrophy in regions susceptible to Alzheimer's disease-related neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e046095	1.2	

999	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046102	1.2	
998	Microglial activation indexed by [11C]PBR28 is associated with synaptic depletion in the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046191	1.2	
997	Hypertension accentuates reductions in CSF A β 2 in elderly depressives. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046299	1.2	
996	Plasma tau is negatively correlated with frontal lobe CBF in hypertensive adults on the AD spectrum. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046355	1.2	
995	SNAP25 reflects amyloid- and tau-related synaptic damage: Associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic dysfunction in the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046358	1.2	2
994	Exploring genetic contributors to neuroprotection from AD pathologies: A genome-wide association study. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046417	1.2	
993	Cerebrospinal fluid phosphorylated tau interacts with MMP2 and MMP3: Associations with cognitive performance in older adults. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046463	1.2	
992	Plasma-based biomarkers for A β and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046490	1.2	
991	Blood-brain barrier permeability measured by 7 β -hydroxy-3-oxo-4-cholestenoic acid in CSF associates with Alzheimer's pathology biomarkers in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046582	1.2	
990	Insulin resistance is related to cognitive decline but not biomarkers of Alzheimer's pathology in adults without dementia. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047022	1.2	
989	Longitudinal changes in established and exploratory cerebrospinal fluid biomarkers by PTAU/A β 2 status in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047156	1.2	
988	CSF proteomic profiling of mild cognitive impairment individuals with suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047247	1.2	1
987	Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routine-use protocol for CSF collection. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047394	1.2	
986	Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047517	1.2	
985	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047539	1.2	2
984	Alzheimer's pathologic change indexed by CSF B-amyloid42 associates with longitudinal alterations in myelin content. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047629	1.2	
983	Ultra-performance liquid chromatography-tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture. <i>Alzheimer's and Dementia</i> , 2020 , 16, e040373	1.2	
982	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. <i>Nature Communications</i> , 2020 , 11, 6252	17.4	15

981	Steroid-Responsive Encephalitis in Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2020 , 88, 423-427	9.4	166
980	Intrathecal immunoreactivity in people with or without previous infectious mononucleosis. <i>Acta Neurologica Scandinavica</i> , 2020 , 142, 161-168	3.8	2
979	Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 1143-1156	4.3	4
978	Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 75, 937-947	4.3	4
977	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, 883-895	1.2	5
976	Losing the identity of a hockey player: the long-term effects of concussions. <i>Concussion</i> , 2020 , 5, CNC74	1.8	3
975	A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 94, 60-70	5.6	13
974	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. <i>Lancet Neurology</i> , 2020 , 19, 513-524	14.1	53
973	APOE ϵ genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 65	9	13
972	Human plasma biomarker responses to inhalational general anaesthesia without surgery. <i>British Journal of Anaesthesia</i> , 2020 , 125, 282-290	5.4	14
971	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1358-1371	1.2	44
970	Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 941-953	4.3	3
969	Blood Biomarkers: Democratizing Alzheimer's Diagnostics. <i>Neuron</i> , 2020 , 106, 881-883	13.9	15
968	Admission Levels of Total Tau and β Amyloid Isoforms 1-40 and 1-42 in Predicting the Outcome of Mild Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2020 , 11, 325	4.1	1
967	Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 139	5.3	4
966	Dextran- Versus Crystalloid-Based Prime in Cardiac Surgery: A Prospective Randomized Pilot Study. <i>Annals of Thoracic Surgery</i> , 2020 , 110, 1541-1547	2.7	4
965	Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. <i>Neurology</i> , 2020 , 95, e1754-e1759	6.5	166
964	Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid- β 2 and White Matter Microstructure in Cognitively Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 643-656	4.3	2

963	A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020 , 21, 452-458	3.6	8
962	Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2020 , 11, 376	4.1	6
961	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. <i>BMC Medicine</i> , 2020 , 18, 140	11.4	16
960	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. <i>Frontiers in Neurology</i> , 2020 , 11, 149	4.1	8
959	Low CSF/serum ratio of free T4 is associated with decreased quality of life in mild hypothyroidism - A pilot study. <i>Journal of Clinical and Translational Endocrinology</i> , 2020 , 19, 100218	2.4	1
958	APOE- ϵ Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. <i>Cerebral Cortex</i> , 2020 , 30, 4110-4120	5.1	2
957	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 21	9	69
956	Self-reported Sleep Problems Related to Amyloid Deposition in Cortical Regions with High HOMER1 Gene Expression. <i>Cerebral Cortex</i> , 2020 , 30, 2144-2156	5.1	6
955	Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 965-974	4.3	8
954	Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. <i>Molecular Psychiatry</i> , 2020 ,	15.1	29
953	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2020 ,	15.1	8
952	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. <i>Neurology</i> , 2020 , 95, e953-e961	6.5	19
951	CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. <i>IBRO Reports</i> , 2020 , 8, 136-142	2	1
950	Diagnostic and prognostic value of serum NfL and p-Tau in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 960-967	5.5	51
949	Serum Hecpidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-Load. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 291-301	4.3	2
948	CXCL13 in patients with facial palsy caused by varicella zoster virus and <i>Borrelia burgdorferi</i> : a comparative study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020 , 98, 115095	2.9	0
947	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. <i>Molecular Psychiatry</i> , 2020 ,	15.1	30
946	Neurofilament light as a biomarker in traumatic brain injury. <i>Neurology</i> , 2020 , 95, e610-e622	6.5	41

945	Time course and diagnostic utility of NFL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. <i>Neurology</i> , 2020 , 95, e623-e636	6.5	46
944	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <i>Nature Medicine</i> , 2020 , 26, 379-386	50.5	292
943	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. <i>Nature Medicine</i> , 2020 , 26, 387-397	50.5	236
942	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method. <i>Clinical Chemistry</i> , 2020 , 66, 587-597	5.5	8
941	Accelerated neuronal and synaptic maturation by BrainPhys medium increases A β secretion and alters A β peptide ratios from iPSC-derived cortical neurons. <i>Scientific Reports</i> , 2020 , 10, 601	4.9	11
940	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 20	9	13
939	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 19	9	11
938	Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. <i>Human Brain Mapping</i> , 2020 , 41, 2004-2013	5.9	8
937	Cerebrospinal Fluid Levels of Interleukin-8 in Delirium, Dementia, and Cognitively Healthy Patients. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 1363-1372	4.3	8
936	Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. <i>Archives of Toxicology</i> , 2020 , 94, 2517-2522	5.8	20
935	Neurofilament-light in former athletes: a potential biomarker of neurodegeneration and progression. <i>European Journal of Neurology</i> , 2020 , 27, 1170-1177	6	4
934	A β deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020 , 6, eaaz2387	14.3	88
933	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020 , 16, 265-284	15	53
932	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. <i>Neurology</i> , 2020 , 95, e3026-e3035	6.5	13
931	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia. <i>PLoS ONE</i> , 2020 , 15, e0236384	3.7	10
930	Untangling the roles of amyloid and tau in synaptic and axonal loss in the course of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e043169	1.2	
929	Association of plasma neurofilament light chain (pNFL) with neuroimaging markers of neurodegeneration and cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e043060	1.2	
928	White matter microstructure and cerebrospinal fluid biomarkers of Alzheimer's disease in middle-aged cognitively unimpaired participants (the ALFA study). <i>Alzheimer's and Dementia</i> , 2020 , 16, e043027	1.2	

927	Genome-wide study of immune biomarkers in cerebrospinal fluid and serum from patients with bipolar disorder and controls. <i>Translational Psychiatry</i> , 2020 , 10, 58	8.6	5
926	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. <i>Nature Communications</i> , 2020 , 11, 619	17.4	37
925	Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study. <i>Scientific Reports</i> , 2020 , 10, 22400	4.9	1
924	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020 , 143, 3776-3792	11.2	16
923	Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 617-625	3.1	7
922	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. <i>Alzheimer's and Dementia</i> , 2020 , 16, 262-272	1.2	29
921	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. <i>Neurobiology of Disease</i> , 2020 , 134, 104645	7.5	12
920	Chemical imaging of evolving amyloid plaque pathology and associated A β peptide aggregation in a transgenic mouse model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2020 , 152, 602-616	6	8
919	Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. <i>BMC Neurology</i> , 2020 , 20, 10	3.1	22
918	Neuroinflammatory markers associate with cognitive decline after major surgery: Findings of an explorative study. <i>Annals of Neurology</i> , 2020 , 87, 370-382	9.4	12
917	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 8	9	6
916	Circulating levels of vascular endothelial growth factor and post-stroke long-term functional outcome. <i>Acta Neurologica Scandinavica</i> , 2020 , 141, 405-414	3.8	2
915	Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men. <i>Neurology</i> , 2020 , 94, e1181-e1189	6.5	29
914	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 88, 83-90	5.6	3
913	Glycan biomarkers for Alzheimer disease correlate with T-tau and P-tau in cerebrospinal fluid in subjective cognitive impairment. <i>FEBS Journal</i> , 2020 , 287, 3221-3234	5.7	17
912	Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 3	9	10
911	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020 , 94, e30-e41	6.5	13
910	Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. <i>Brain</i> , 2020 , 143, 650-660	11.2	33

909	An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. <i>Current Opinion in Neurobiology</i> , 2020 , 61, 29-39	7.6	43
908	Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders. <i>Movement Disorders</i> , 2020 , 35, 513-518		11
907	Postoperative delirium is associated with increased plasma neurofilament light. <i>Brain</i> , 2020 , 143, 47-54	11.2	42
906	CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults. <i>Cerebral Cortex</i> , 2020 , 30, 2295-2306	5.1	10
905	The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020 , 270, 911-919	5.1	3
904	Quality of life of ice hockey players after retirement due to concussions. <i>Concussion</i> , 2020 , 5, CNC78	1.8	2
903	Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults. <i>Frontiers in Neurology</i> , 2020 , 11, 1054	4.1	18
902	Biomarkers of neuronal damage in saturation diving-a controlled observational study. <i>European Journal of Applied Physiology</i> , 2020 , 120, 2773-2784	3.4	2
901	Beta-secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 130	9	2
900	Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1429-1442	5.3	2
899	Association of plasma YKL-40 with brain amyloid- β levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 96, 22-32	5.6	4
898	Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology. <i>Brain Communications</i> , 2020 , 2, fcaa099	4.5	2
897	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 88	9	6
896	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2020 ,	15.1	36
895	NFL as a biomarker for neurodegeneration and survival in Parkinson disease. <i>Neurology</i> , 2020 , 95, e827-e838	6.3	28
894	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020 , 143, 3793-3804	11.2	20
893	Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 153	9	2
892	Admission Levels of Interleukin 10 and Amyloid β -40 Improve the Outcome Prediction Performance of the Helsinki Computed Tomography Score in Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2020 , 11, 549527	4.1	4

891	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020 , 10, 403	8.6	10
890	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 147	9	8
889	Fluid Biomarkers for Chronic Traumatic Encephalopathy. <i>Seminars in Neurology</i> , 2020 , 40, 411-419	3.2	2
888	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 772-781	27.4	268
887	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020 , 140, 267-278	14.3	79
886	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 95, 143-153	5.6	17
885	Reliability of serum S100B measurement following mild traumatic brain injury: a comparison of assay measurements from two laboratories. <i>Brain Injury</i> , 2020 , 34, 1237-1244	2.1	2
884	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 1661-1673	5.3	14
883	NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102463	4	6
882	Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury. <i>Scientific Reports</i> , 2020 , 10, 18075	4.9	8
881	Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism. <i>Brain Connectivity</i> , 2020 , 10, 555-565	2.7	6
880	Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events. <i>In Vivo</i> , 2020 , 34, 2577-2586	2.3	6
879	Fatty Acid-Binding Protein 3 in Cerebrospinal Fluid of Hip Fracture Patients with Delirium. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 183-190	4.3	0
878	Cognitive Dispersion Is Not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Results from the European Prevention of Alzheimer's Dementia (EPAD) v500.0 Cohort. <i>Journal of Alzheimer's Disease</i> , 2020 , 78, 185-194	4.3	1
877	Neurofilament light chain in the vitreous humor of the eye. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 111	9	4
876	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1129-1141	4.3	25
875	First amyloid β -42 certified reference material for re-calibrating commercial immunoassays. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1493-1503	1.2	20
874	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1353-1368	4.3	4

873	Extensive Plasmid Library to Prepare Tau Protein Variants and Study Their Functional Biochemistry. <i>ACS Chemical Neuroscience</i> , 2020 , 11, 3117-3129	5.7	4
872	Fluid Biomarkers for Synaptic Dysfunction and Loss. <i>Biomarker Insights</i> , 2020 , 15, 1177271920950319	3.5	23
871	Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus. <i>Journal of NeuroVirology</i> , 2020 , 26, 719-726	3.9	3
870	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. <i>PLoS ONE</i> , 2020 , 15, e0233820	3.7	3
869	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020 , 17, e1003289	11.6	15
868	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A β pathology are detected. <i>EMBO Molecular Medicine</i> , 2020 , 12, e12921	12	67
867	The impact of social networks and β on dementia among older adults: tests of possible interactions. <i>Aging and Mental Health</i> , 2020 , 24, 395-404	3.5	7
866	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. <i>Molecular Psychiatry</i> , 2020 , 25, 2919-2931	15.1	51
865	Acute symptomatic seizures and epilepsy after mechanical thrombectomy. <i>Epilepsy and Behavior</i> , 2020 , 104, 106520	3.2	14
864	Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. <i>Biological Psychiatry</i> , 2020 , 87, 808-818	7.9	25
863	Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study. <i>Neurobiology of Aging</i> , 2020 , 86, 54-63	5.6	69
862	Dementia and CSF-biomarkers for Alzheimer's disease predict mortality after acute hip fracture. <i>Acta Anaesthesiologica Scandinavica</i> , 2020 , 64, 93-103	1.9	11
861	Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020 , 270, 933-938	5.1	2
860	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , 2020 , 19, 422-433	24.1	286
859	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2020 , 93, 1-15	5.6	6
858	Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 1211-1220	4.3	10
857	Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy. <i>Frontiers in Neurology</i> , 2020 , 11, 586610	4.1	2
856	Steroid-Responsive Encephalitis in Coronavirus Disease 2019 2020 , 88, 423		1

855	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12099	5.2	8
854	Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12137	5.2	9
853	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 2020 , 17, e1003289		
852	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 2020 , 17, e1003289		
851	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 2020 , 17, e1003289		
850	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 2020 , 17, e1003289		
849	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 2020 , 17, e1003289		
848	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 2020 , 17, e1003289		
847	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 2020 , 17, e1003289		
846	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease 2020 , 15, e0233820		
845	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease 2020 , 15, e0233820		
844	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease 2020 , 15, e0233820		
843	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease 2020 , 15, e0233820		
842	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia 2020 , 15, e0236384		
841	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia 2020 , 15, e0236384		
840	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia 2020 , 15, e0236384		
839	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia 2020 , 15, e0236384		
838	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 5	7.3	79

837	Was it worth it? Older adults' experiences of participating in a population-based cohort study - a focus group study. <i>BMC Geriatrics</i> , 2019 , 19, 224	4.1	10
836	Growth factors and neurotrophins in patients with stress-related exhaustion disorder. <i>Psychoneuroendocrinology</i> , 2019 , 109, 104415	5	9
835	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1478-1488	1.2	22
834	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019 , 83, 42-53	5.6	23
833	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 82	9	26
832	CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 81	9	42
831	Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2019 , 71, 281-290	4.3	6
830	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 679-689	5.2	31
829	Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection. <i>Infectious Diseases</i> , 2019 , 51, 838-846	3.1	3
828	Age-Dependent Relationship Between Plasma A β 0 and A β 2 and Total Tau Levels in Cognitively Normal Subjects. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 222	5.3	15
827	NFL blood levels are moderated by subconcussive impacts in a cohort of college football players. <i>Brain Injury</i> , 2019 , 33, 456-462	2.1	31
826	Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. <i>Journal of Neuroinflammation</i> , 2019 , 16, 16	10.1	13
825	Head trauma in sports and risk for dementia. <i>Journal of Internal Medicine</i> , 2019 , 285, 591-593	10.8	1
824	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019 , 138, 237-250	14.3	50
823	Elecsys Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. <i>Clinical Biochemistry</i> , 2019 , 72, 30-38	3.5	37
822	Method comparison study of the Elecsys β -Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. <i>Clinical Biochemistry</i> , 2019 , 72, 7-14	3.5	18
821	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , 2019 , 76, 1035-1048	17.2	237
820	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β -Amyloid Status. <i>JAMA Neurology</i> , 2019 , 76, 1060-1069	17.2	159

819	CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 1117-1123	5.5	32
818	NFL is a marker of treatment response in children with SMA treated with nusinersen. <i>Journal of Neurology</i> , 2019 , 266, 2129-2136	5.5	61
817	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2019 , 266, 2157-2163	5.5	22
816	Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women. <i>Neurobiology of Aging</i> , 2019 , 80, 111-115	5.6	4
815	Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019 , 28, 2242-2249	2.8	28
814	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. <i>Alzheimer's and Dementia</i> , 2019 , 15, 888-898	1.2	131
813	Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. <i>Neurology</i> , 2019 , 93, e252-e260	6.5	81
812	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 1213-1220	4.3	8
811	Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2019 , 76, 969-977	17.2	39
810	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019 , 15, 817-827	1.2	26
809	Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism. <i>Acta Neurologica Scandinavica</i> , 2019 , 140, 147-156	3.8	12
808	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 764-775	1.2	86
807	Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 551-559	4.3	3
806	Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapy-A pilot study. <i>Journal of Affective Disorders</i> , 2019 , 253, 449-453	6.6	11
805	Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases. <i>Acta Neurologica Scandinavica</i> , 2019 , 140, 177-183	3.8	1
804	A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019 , 36, 2850-2862	5.4	78
803	CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 846-853	5.5	27
802	Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 129-138	6	16

801	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2019 , 76, 791-799	17.2	228
800	Identification of neurotoxic cross-linked amyloid- β dimers in the Alzheimer's brain. <i>Brain</i> , 2019 , 142, 1441-1457	11.57	40
799	Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke. <i>Journal of Internal Medicine</i> , 2019 , 286, 101-110	10.8	16
798	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 27	9	45
797	Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. <i>Clinica Chimica Acta</i> , 2019 , 494, 79-93	6.2	17
796	Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries. <i>Journal of Neurotrauma</i> , 2019 , 36, 2400-2406	5.4	16
795	Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. <i>PLoS ONE</i> , 2019 , 14, e0212815	3.7	4
794	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019 , 15, 644-654	1.2	57
793	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019 , 15, 742-753	1.2	50
792	Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid- β and tau. <i>Neurobiology of Aging</i> , 2019 , 80, 11-20	5.6	54
791	Neurofilament light chain as a biomarker in neurological disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 870-881	5.5	250
790	Amyloid β 2 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019 , 47, 114-124	2.6	1
789	Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1565-1573	5.9	6
788	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 740-746	5.5	14
787	Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 111-121	4.3	3
786	CSF and blood biomarkers for Parkinson's disease. <i>Lancet Neurology</i> , 2019 , 18, 573-586	24.1	180
785	APOE ϵ 4 and the long arm of social inequity: estimated effects of socio-economic status and sex on the timing of dementia onset. <i>Ageing and Society</i> , 2019 , 39, 1951-1975	1.7	5
784	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019 , 79, 131-141	5.6	12

783	Mass Spectrometric Analysis of Lewy Body-Enriched β Synuclein in Parkinson's Disease. <i>Journal of Proteome Research</i> , 2019 , 18, 2109-2120	5.6	19
782	Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer's disease patients. <i>Scientific Reports</i> , 2019 , 9, 5522	4.9	12
781	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. <i>Scientific Reports</i> , 2019 , 9, 2460	4.9	2
780	Increased Secondary Nucleation Underlies Accelerated Aggregation of the Four-Residue N-Terminally Truncated A β 2 Species A β -42. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 2374-2384	5.7	11
779	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 19	9	47
778	Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. <i>Molecular and Cellular Neurosciences</i> , 2019 , 97, 34-42	4.8	33
777	Sleep oscillation-specific associations with Alzheimer's disease CSF biomarkers: novel roles for sleep spindles and tau. <i>Molecular Neurodegeneration</i> , 2019 , 14, 10	19	30
776	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019 , 5, eaau7220	14.3	44
775	Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis. <i>Schizophrenia Research</i> , 2019 , 208, 490-492	3.6	2
774	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis. <i>Cellular and Molecular Life Sciences</i> , 2019 , 76, 1833-1863	10.3	46
773	Measuring longitudinal cognition: Individual tests versus composites. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 74-84	5.2	27
772	Sleep deprivation and plasma biomarkers for Alzheimer's disease. <i>Sleep Medicine</i> , 2019 , 57, 92-93	4.6	4
771	Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. <i>Acta Neurologica Scandinavica</i> , 2019 , 139, 462-468	3.8	13
770	Peptidomic analysis of cartilage and subchondral bone in OA patients. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13082	4.6	4
769	Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology. <i>Journal of Neurochemistry</i> , 2019 , 151, 488-506	6	15
768	Antibody-based methods for the measurement of β Synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019 , 149, 126-138	6	26
767	Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study. <i>Neuropsychobiology</i> , 2019 , 77, 13-22	4	11
766	Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. <i>Mitochondrion</i> , 2019 , 46, 228-235	4.9	5

765	The gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	77
764	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 35, 228-232	4	11
763	Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction. <i>Journal of Neurology</i> , 2019 , 266, 2796-2806	5.5	25
762	Plasma neurofilament light chain concentration is increased in anorexia nervosa. <i>Translational Psychiatry</i> , 2019 , 9, 180	8.6	13
761	Ultrasensitive Detection of Plasma Amyloid- β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 71, 775-783	4.3	29
760	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease.. <i>Clinical Mass Spectrometry</i> , 2019 , 14 Pt B, 74-82	1.9	1
759	Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 483-492	5.2	48
758	Characterization of Cerebrospinal Fluid BACE1 Species. <i>Molecular Neurobiology</i> , 2019 , 56, 8603-8616	6.2	4
757	Sex differences in the genetic predictors of Alzheimer's pathology. <i>Brain</i> , 2019 , 142, 2581-2589	11.2	32
756	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 120	7.3	35
755	Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimer's disease. <i>Brain Research</i> , 2019 , 1720, 146305	3.7	16
754	Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum. <i>NeuroImage: Clinical</i> , 2019 , 23, 101895	5.3	21
753	Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1556-1564	5.9	23
752	Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data. <i>Journal of the American Society for Mass Spectrometry</i> , 2019 , 30, 2278-2288	3.5	4
751	Plasma neurofilament light chain and amyloid- β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2019 , 16, 186	10.1	28
750	Autocatalytic amplification of Alzheimer-associated A β 2 peptide aggregation in human cerebrospinal fluid. <i>Communications Biology</i> , 2019 , 2, 365	6.7	28
749	Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 72, 525-535	4.3	9
748	Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1437-1447	1.2	20

747	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2019 , 11, e11170	12	113
746	Detection of early-stage Alzheimer's pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients. <i>PLoS ONE</i> , 2019 , 14, e0225178	3.7	8
745	Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 700-709	5.2	15
744	Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas. <i>World Journal of Oncology</i> , 2019 , 10, 169-175	16.7	13
743	A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer's disease. <i>Neuroscience Letters</i> , 2019 , 701, 125-131	3.3	25
742	Pyroglutamation of amyloid- β -42 (A β -42) followed by A β -40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. <i>Journal of Biological Chemistry</i> , 2019 , 294, 6719-6732	5.4	30
741	Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019 , 36, 2178-2189	5.4	27
740	FTS3-01-01: UMIBECESTAT (CNP520) IS NOT ASSOCIATED WITH CHANGES IN HIPPOCAMPAL MORPHOLOGY IN RATS OR CHANGES IN CSF AD BIOMARKERS IN HUMANS TREATED FOR 3 MONTHS 2019 , 15, P872-P872		1
739	P4-531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO β AMYLOID POSITIVITY 2019 , 15, P1517-P1519		
738	P4-546: THE NEURAL CELL ADHESION PROTEIN NEUROLIGIN 1 IN ALZHEIMER'S DISEASE 2019 , 15, P1526-P1526		
737	P4-579: LOWER NEURITE DENSITY AND ORIENTATION DISPERSION WITHIN GRAY AND WHITE MATTER IN THE ALZHEIMER'S DISEASE PATHOLOGIC FRAMEWORK 2019 , 15, P1542-P1543		
736	Altered CSF levels of monoamines in hereditary spastic paraparesis 10: A case series. <i>Neurology: Genetics</i> , 2019 , 5, e344	3.8	2
735	CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 105	9	17
734	P4-573: PROXIMITY TO PARENTAL ONSET AND APOE ϵ INDEPENDENTLY CONTRIBUTE TO AMYLOID BURDEN IN MIDDLE-AGED ADULTS WITH A FAMILY HISTORY OF SPORADIC ALZHEIMER'S DISEASE 2019 , 15, P1539-P1539		
733	P4-525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE 2019 , 15, P1515-P1516		
732	CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6,	9.1	4
731	O3-02-01: APOE- ϵ ALLELIC LOAD MODULATES THE ASSOCIATION BETWEEN CSF BETA-AMYLOID AND GRAY MATTER VOLUME IN COGNITIVELY UNIMPAIRED INDIVIDUALS 2019 , 15, P877-P878		
730	F4-05-01: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER'S DISEASE 2019 , 15, P1224-P1225		

729	P4-535: PRESENTATION OF A ROUTINE-USE PRE-ANALYTICAL PROCEDURE FOR AD CSF BIOMARKERS 2019 , 15, P1520-P1521		
728	P4-589: COMPARISON OF CEREBROSPINAL FLUID NEUROFILAMENT LIGHT CHAIN PROTEIN AND THREE MRI-BASED MORPHOMETRIC ESTIMATES FOR DEFINING NEURODEGENERATION (N) ACROSS THE ALZHEIMER'S DISEASE CONTINUUM 2019 , 15, P1547-P1548		
727	O2-05-01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE 2019 , 15, P545-P545		2
726	IC-P-093: PLASMA AMYLOID-BETA AND TAU AND VISUAL CONTRAST SENSITIVITY SYNERGISTICALLY PREDICT CEREBRAL AMYLOID AND TAU DEPOSITION ON PET IN PRECLINICAL AND PRODROMAL AD 2019 , 15, P82-P82		
725	Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder. <i>Biomarkers in Neuropsychiatry</i> , 2019 , 1, 100007-100007	3.8	4
724	P4-519: MOLECULAR FORMS OF NEUROGRANIN IN CEREBROSPINAL FLUID 2019 , 15, P1513-P1513		
723	IC-P-070: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER'S DISEASE 2019 , 15, P64-P65		1
722	IC-P-071: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER'S DISEASE 2019 , 15, P65-P66		
721	IC-P-072: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXEL-BASED MORPHOMETRY IN ALZHEIMER'S DISEASE 2019 , 15, P66-P66		
720	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 933-938	6	29
719	IC-P-015: VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE CONTINUUM 2019 , 15, P24-P25		
718	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 94	9	15
717	Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. <i>Progress in Molecular Biology and Translational Science</i> , 2019 , 168, 3-23	4	11
716	Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. <i>Scientific Reports</i> , 2019 , 9, 17309	4.9	1
715	Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. <i>Nature Medicine</i> , 2019 , 25, 1680-1683	50.5	171
714	Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep. <i>PLoS ONE</i> , 2019 , 14, e0226697	3.7	7
713	Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays. <i>Scientific Reports</i> , 2019 , 9, 19024	4.9	50
712	Repeated lumbar punctures within 3 days may affect CSF biomarker levels. <i>Fluids and Barriers of the CNS</i> , 2019 , 16, 37	7	3

711	Salivary Biomarkers for Alzheimer's Disease and Related Disorders. <i>Neurology and Therapy</i> , 2019 , 8, 83-94.6	24
710	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2019 , 97, 3-17	4.8 51
709	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2019 , 124, 428-438	7.5 7
708	Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. <i>Neuroscience Letters</i> , 2019 , 698, 58-63	3.3 37
707	The Gothenburg H70 Birth cohort study 2014-16: design, methods and study population. <i>European Journal of Epidemiology</i> , 2019 , 34, 191-209	12.1 44
706	Head trauma in sports - clinical characteristics, epidemiology and biomarkers. <i>Journal of Internal Medicine</i> , 2019 , 285, 624-634	10.8 22
705	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. <i>JAMA Neurology</i> , 2019 , 76, 187-193	17.2 42
704	The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 415-419	3.9 5
703	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. <i>Current HIV/AIDS Reports</i> , 2019 , 16, 76-81	5.9 4
702	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1152-1163	8.8 23
701	Association of PTHrP levels in CSF with Alzheimer's disease biomarkers.. <i>Clinical Mass Spectrometry</i> , 2019 , 14 Pt B, 124-129	1.9 3
700	Accurate risk estimation of amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , 2019 , 15, 194-204	1.2 31
699	Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. <i>JAMA Neurology</i> , 2019 , 76, 64-71	17.2 85
698	Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 55-64	1.2 50
697	Vitamin D supplementation and neurofilament light chain in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2019 , 139, 172-176	3.8 10
696	Biomarkers for tau pathology. <i>Molecular and Cellular Neurosciences</i> , 2019 , 97, 18-33	4.8 96
695	Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis. <i>NeuroImage: Clinical</i> , 2019 , 21, 101586	5.3 23
694	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019 , 137, 279-296	14.3 79

693	Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019 , 36, 1551-1560	5.4	26
692	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , 2019 , 76, 318-325	17.2	94
691	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. <i>Neuroscience</i> , 2019 , 420, 136-144	3.9	12
690	Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2019 , 151, 417-434	6	10
689	The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019 , 137, 89-102	14.3	47
688	GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019 , 1867, 458-467	4	19
687	Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults. <i>Brain Imaging and Behavior</i> , 2019 , 13, 41-52	4.1	22
686	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate 2019 , 14, e0226276		
685	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate 2019 , 14, e0226276		
684	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate 2019 , 14, e0226276		
683	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate 2019 , 14, e0226276		
682	Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 188-195	5.2	35
681	Induction of Amyloid- β 2 Production by Fipronil and Other Pyrazole Insecticides. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1663-1681	4.3	20
680	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018 , 64, 927-937	5.5	27
679	CSF biomarkers of Alzheimer's disease concord with amyloid- β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1470-1481	1.2	266
678	Low Cerebrospinal Fluid A β 2 and A β 0 are Related to White Matter Lesions in Cognitively Normal Elderly. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1877-1886	4.3	9
677	Neurofilament light and tau as blood biomarkers for sports-related concussion. <i>Neurology</i> , 2018 , 90, e1780-e1788	6.5	90
676	Cerebrospinal fluid markers of extracellular matrix remodelling, synaptic plasticity and neuroinflammation before and after cranial radiotherapy. <i>Journal of Internal Medicine</i> , 2018 , 284, 211	10.8	8

675	Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. <i>Journal of Neurotrauma</i> , 2018 , 35, 2351-2356	5.4	27
674	Plasma Amyloid- β (A β 2) Correlates with Cerebrospinal Fluid A β 2 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1857-1863	4.3	61
673	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 535-562	1.2	3155
672	Association of Plasma Neurofilament Light Chain with Neocortical Amyloid- β Load and Cognitive Performance in Cognitively Normal Elderly Participants. <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 479-487	4.3	30
671	Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry. <i>ACS Chemical Neuroscience</i> , 2018 , 9, 1802-1817	5.7	35
670	Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study. <i>Acta Neurologica Scandinavica</i> , 2018 , 138, 143-150	3.8	13
669	The Past and the Future of Alzheimer's Disease Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1125-1140	4.3	69
668	Prevalence of preclinical Alzheimer disease: Comparison of current classification systems. <i>Neurology</i> , 2018 , 90, e1682-e1691	6.5	48
667	Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery: Results From the CAPACITY and ARCADIAN Studies. <i>JAMA Neurology</i> , 2018 , 75, 542-547	17.2	57
666	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. <i>Alzheimer's and Dementia</i> , 2018 , 14, 751-763	1.2	45
665	Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link. <i>EBioMedicine</i> , 2018 , 28, 21-30	8.8	131
664	Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 385-397	4.3	49
663	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. <i>Neurology</i> , 2018 , 90, e877-e886	6.5	15
662	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 417-427	4.3	4
661	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. <i>Neurology</i> , 2018 , 90, e717-e723	6.5	42
660	Genetic Variation in FOXO3 is Associated with Self-Rated Health in a Population-Based Sample of Older Individuals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018 , 73, 1453-1458	6.4	7
659	Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease. <i>Sleep</i> , 2018 , 41,	1.1	46
658	Evolution of cerebrospinal fluid total β synuclein in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 49, 4-8	3.6	23

657	Comparing F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018 , 90, e388-e395	6.5	62
656	Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. <i>Neurology</i> , 2018 , 90, e518-e524	6.5	107
655	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 162-171	5.3	23
654	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A β total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. <i>Alzheimer's and Dementia</i> , 2018 , 14, 492-501	1.2	71
653	Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. <i>Brain</i> , 2018 , 141, 459-471	11.2	100
652	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 8	9	62
651	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 30	9	29
650	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018 , 136, 363-376	14.3	83
649	Cerebrospinal fluid β amyloid and neurofilament light relate to white matter hyperintensities. <i>Neurobiology of Aging</i> , 2018 , 68, 18-25	5.6	29
648	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 913-924	1.2	36
647	Apolipoprotein E genotypes and longevity across dementia disorders. <i>Alzheimer's and Dementia</i> , 2018 , 14, 895-901	1.2	6
646	Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <i>Scientific Reports</i> , 2018 , 8, 4260	4.9	17
645	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2018 , 83, 447-455	7.9	62
644	Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1046-1054	5	113
643	Neuroinflammation and Tau Interact with Amyloid in Predicting Sleep Problems in Aging Independently of Atrophy. <i>Cerebral Cortex</i> , 2018 , 28, 2775-2785	5.1	21
642	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 244-328	3.8	148
641	A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. <i>Proteomics - Clinical Applications</i> , 2018 , 12, 1700131	3.1	62
640	Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2018 , 137, 91-98	3.8	16

639	Inhibition of β Secretase Leads to an Increase in Presenilin-1. <i>Molecular Neurobiology</i> , 2018 , 55, 5047-5058	6.2	13
638	Commutability of the certified reference materials for the standardization of β amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β amyloid 1-40 measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 2058-2066	5.9	23
637	Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. <i>Experimental Neurology</i> , 2018 , 307, 129-132	5.7	29
636	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1313-1333	1.2	61
635	No association of salivary total tau concentration with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 70, 125-127	5.6	35
634	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. <i>Neurology</i> , 2018 , 91, e867-e877	6.5	120
633	Biomarkers for Alzheimer's disease: current status and prospects for the future. <i>Journal of Internal Medicine</i> , 2018 , 284, 643-663	10.8	278
632	Levels of ADAM10 are reduced in Alzheimer's disease CSF. <i>Journal of Neuroinflammation</i> , 2018 , 15, 213	10.1	24
631	Association of cerebrospinal fluid β synuclein with total and phospho-tau protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1623-1631	1.2	30
630	Evidence for sex difference in the CSF/plasma albumin ratio in ~20 000 patients and 335 healthy volunteers. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 5151-5154	5.6	30
629	Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 71	9	141
628	Cerebrospinal fluid tau, A β and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1159-1170	1.2	64
627	Commentary: Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Frontiers in Neurology</i> , 2018 , 9, 201	4.1	21
626	The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain. <i>Cell Death and Disease</i> , 2018 , 9, 775	9.8	7
625	Effects of APOE ϵ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 71, 81-90	5.6	8
624	Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NFL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study. <i>PLoS ONE</i> , 2018 , 13, e0196025	3.7	20
623	Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2018 , 15, 209	10.1	64
622	The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 62	7.3	3

621	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 5	9	63
620	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 32	9	57
619	Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. <i>JAMA Neurology</i> , 2018 , 75, 989-998	17.2	142
618	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 45	9	5
617	Cerebrospinal fluid GAP-43 in early multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318792931	2	4
616	Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project: Goals and Progress to Date. <i>Journal of Proteome Research</i> , 2018 , 17, 4072-4084	5.6	3
615	Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018 , 46, 90-99	2.6	6
614	Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2018 , 24, 695-701	3.9	21
613	Serum neurofilament light chain in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 98-101	3.6	26
612	Update on biomarkers for amyloid pathology in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2018 , 12, 799-812	2.3	39
611	Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease. <i>PLoS ONE</i> , 2018 , 13, e0193492	3.7	10
610	The nonlinear relationship between cerebrospinal fluid A β 2 and tau in preclinical Alzheimer's disease. <i>PLoS ONE</i> , 2018 , 13, e0191240	3.7	23
609	The 12-Word Philadelphia Verbal Learning Test Performances in Older Adults: Brain MRI and Cerebrospinal Fluid Correlates and Regression-Based Normative Data. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018 , 8, 476-491	2.5	3
608	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
607	CSF neurofilament light concentration is increased in presymptomatic mutation carriers. <i>Neurology</i> , 2018 , 90, e157-e163	6.5	10
606	Increased midlife triglycerides predict brain β amyloid and tau pathology 20 years later. <i>Neurology</i> , 2018 , 90, e73-e81	6.5	44
605	Central and peripheral leptin and agouti-related protein during and after pregnancy in relation to weight change. <i>Clinical Endocrinology</i> , 2018 , 88, 263-271	3.4	8
604	Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 933-943	10.2	109

- 603 O2-03-05: VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED, LATE MIDDLE-AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION **2018**, 14, P617-P618
- 602 P3-218: NOVEL ALZHEIMER'S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: A β -42, TOTAL-TAU, PHOSPHORYLATED-TAU, NFL, NEUROGRANIN, AND YKL-40 **2018**, 14, P1154-P1155 1
- 601 P3-161: ALTERATIONS IN ALZHEIMER-ASSOCIATED SYNAPTIC MARKERS FOLLOWING IRRADIATION OF STEM CELL-DERIVED CORTICAL NEURONS **2018**, 14, P1129-P1130
- 600 P3-267: ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS **2018**, 14, P1178-P1179 1
- 599 P1-188: MODELLING AMYLOID BETA PROFILES IN IPSC-DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE **2018**, 14, P350-P351
- 598 P2-273: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING **2018**, 14, P782-P782
- 597 O2-04-04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE **2018**, 14, P623-P624
- 596 P1-007: POOR SLEEP IS ASSOCIATED WITH CSF-MARKERS OF ALZHEIMER'S DISEASE IN 70-YEAR-OLDS WITHOUT DEMENTIA **2018**, 14, P265-P265
- 595 F2-02-01: NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD **2018**, 14, P603-P603
- 594 IC-P-018: VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED LATE MIDDLE-AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION **2018**, 14, P23-P24 2
- 593 P1-217: PROTEOLYTIC PROCESSING OF THE SYNAPTIC ALZHEIMER BIOMARKER NEUROGRANIN BY CALPAIN I AND PROLYL ENDOPEPTIDASE **2018**, 14, P361-P362
- 592 P1-139: THE CONTRIBUTION OF SEX-SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY **2018**, 14, P327-P328
- 591 P1-279: BIMODAL DISTRIBUTION OF THE CSF A β 2/A β 0 RATIO IN CLINICAL LABORATORY PRACTICE **2018**, 14, P389-P390
- 590 P1-026: CEREBROSPINAL FLUID TAU, A β AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION **2018**, 14, P275-P276
- 589 Transient increase in CSF GAP-43 concentration after ischemic stroke. *BMC Neurology*, **2018**, 18, 202 3.1 14
- 588 P2-237: ASSOCIATION OF CSF ALPHA-SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS **2018**, 14, P762-P762
- 587 O3-09-02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOID-PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS **2018**, 14, P1036-P1037
- 586 P4-186: INNOVATIVE BIOMARKER-GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA **2018**, 14, P1510-P1511

585	P1-262: NEUROFILAMENT LIGHT PROTEIN IS ASSOCIATED WITH COGNITIVE DECLINE WITHIN THE ATN MODEL 2018 , 14, P381-P382		
584	P3-261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE 2018 , 14, P1174-P1175		
583	Chronic traumatic encephalopathy: fluid biomarkers. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018 , 158, 323-333	3	9
582	CSF sTREM2 in delirium-relation to Alzheimer's disease CSF biomarkers A β 2, t-tau and p-tau. <i>Journal of Neuroinflammation</i> , 2018 , 15, 304	10.1	17
581	P2-246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKL-40 CONCENTRATIONS IN AMYLOID-PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P767-P768		
580	DT-02-04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA A β BIOMARKER ASSAYS 2018 , 14, P1670-P1670		1
579	P1-001: CSF CHOLINE ACETYLTRANSFERASE SHOWS DIFFERENTIAL LEVELS AMONG HEALTHY CONTROLS AND PATIENTS WITH AD AND MCI 2018 , 14, P261-P261		
578	The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 124	9	156
577	Neurofilament Light in Serum and Cerebrospinal Fluid of Hip Fracture Patients with Delirium. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018 , 46, 346-357	2.6	19
576	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018 , 136, 821-853	14.3	236
575	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018 , 14, 639-652	15	257
574	Interlaboratory validation of cerebrospinal fluid β -synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 461-470	5.2	5
573	Abnormal CSF amyloid- β 2 and tau levels in hip fracture patients without dementia. <i>PLoS ONE</i> , 2018 , 13, e0204695	3.7	14
572	Heading in soccer increases serum neurofilament light protein and SCAT3 symptom metrics. <i>BMJ Open Sport and Exercise Medicine</i> , 2018 , 4, e000433	3.4	34
571	Effects of methylprednisolone on blood-brain barrier and cerebral inflammation in cardiac surgery-a randomized trial. <i>Journal of Neuroinflammation</i> , 2018 , 15, 283	10.1	22
570	Cerebrospinal fluid protein markers in PD patients after DBS-STN surgery-A retrospective analysis of patients that underwent surgery between 1993 and 2001. <i>Clinical Neurology and Neurosurgery</i> , 2018 , 174, 174-179	2	2
569	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1505-1521	1.2	97
568	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. <i>Nutrition Research</i> , 2018 , 60, 13-25	4	7

567	Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study. <i>Neurology</i> , 2018 , 91, e2045-e2056	6.5	70
566	No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion. <i>PLoS ONE</i> , 2018 , 13, e0206466	3.7	22
565	DT-02-01: APPROPRIATE USE CRITERIA FOR LUMBAR PUNCTURE AND CEREBROSPINAL FLUID TESTING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE 2018 , 14, P1668-P1669		
564	Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons. <i>Neurochemistry International</i> , 2018 , 121, 38-49	4.4	13
563	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 87	9	8
562	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A β species. <i>NeuroImage: Clinical</i> , 2018 , 20, 603-610	5.3	7
561	Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase. <i>Molecular Neurodegeneration</i> , 2018 , 13, 47	19	18
560	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018 , 14, 577-589	15	627
559	From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S271-S279	4.3	44
558	Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals A β Aggregation Dependent Anionic Lipid Accumulations and Metabolism. <i>Analytical Chemistry</i> , 2018 , 90, 8130-8138	7.8	24
557	Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review. <i>European Neuropsychopharmacology</i> , 2018 , 28, 783-794	1.2	11
556	A 10-Year Follow-Up of Adiposity and Dementia in Swedish Adults Aged 70 Years and Older. <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 1325-1335	4.3	6
555	Neurofilament relates to white matter microstructure in older adults. <i>Neurobiology of Aging</i> , 2018 , 70, 233-241	5.6	34
554	Trisomy of human chromosome 21 enhances amyloid- β deposition independently of an extra copy of APP. <i>Brain</i> , 2018 , 141, 2457-2474	11.2	64
553	Socioeconomic status, gender and dementia: The influence of work environment exposures and their interactions with e4. <i>SSM - Population Health</i> , 2018 , 5, 171-179	3.8	17
552	Sex-specific genetic predictors of Alzheimer's disease biomarkers. <i>Acta Neuropathologica</i> , 2018 , 136, 857-872	14.3	48
551	HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain. <i>Molecular Neurobiology</i> , 2017 , 54, 188-199	6.2	8
550	CSF A β an excellent but complicated Alzheimer's biomarker - a route to standardisation. <i>Clinica Chimica Acta</i> , 2017 , 467, 27-33	6.2	82

549	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 62-71	5	64
548	Genome-wide association study identifies locus influencing human plasma tau levels. <i>Neurology</i> , 2017 , 88, 669-676	6.5	26
547	Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 778-782	1.2	61
546	Neurofilament Protein and Antineurofilament Antibodies Following Traumatic Brain Injury-Reply. <i>JAMA Neurology</i> , 2017 , 74, 363-364	17.2	4
545	Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. <i>Translational Psychiatry</i> , 2017 , 7, e995	8.6	48
544	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 543-555	4.3	7
543	CSF YKL-40 and GAP-43 are related to suicidal ideation in older women. <i>Acta Psychiatrica Scandinavica</i> , 2017 , 135, 351-357	6.5	7
542	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. <i>Parkinsonism and Related Disorders</i> , 2017 , 37, 65-71	3.6	24
541	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , 2017 , 13, 903-912	1.2	21
540	The effects of different familial Alzheimer's disease mutations on APP processing in vivo. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 9	9	22
539	Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2017 , 24, 703-712	6	65
538	Astroglial activation and altered amyloid metabolism in human repetitive concussion. <i>Neurology</i> , 2017 , 88, 1400-1407	6.5	27
537	Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. <i>Acta Neuropathologica</i> , 2017 , 133, 839-856	14.3	107
536	Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. <i>Journal of Neuroimmunology</i> , 2017 , 306, 25-30	3.5	16
535	Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017 , 267, 391-402	5.1	11
534	Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017 , 18, 397-403	3.6	49
533	Accuracy of cerebrospinal fluid A β -42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunoassay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017 , 55, 1545-1554	5.9	12
532	Blood-based NFL: A biomarker for differential diagnosis of parkinsonian disorder. <i>Neurology</i> , 2017 , 88, 930-937	6.5	240

531	The immune response of the human brain to abdominal surgery. <i>Annals of Neurology</i> , 2017 , 81, 572-582	9.4	58
530	Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 993-1003	1.2	35
529	Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. <i>Neurology</i> , 2017 , 88, 1788-1794	6.5	184
528	Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 284-290	6	16
527	Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. <i>Brain, Behavior, and Immunity</i> , 2017 , 65, 195-201	16.6	49
526	The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 31	9	27
525	A Season of American Football Is Not Associated with Changes in Plasma Tau. <i>Journal of Neurotrauma</i> , 2017 , 34, 3295-3300	5.4	11
524	Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study. <i>Scientific Reports</i> , 2017 , 7, 3485	4.9	10
523	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2017 , 81, 857-870	9.4	479
522	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017 , 1598, 101-115	1.4	11
521	Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 829-840	4.3	22
520	Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. <i>Brain Research</i> , 2017 , 1668, 12-19	3.7	36
519	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017 , 108, 355-360	4.4	38
518	Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 821-828	4.3	8
517	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017 , 7, 2477	4.9	21
516	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 1245-1254	4.3	41
515	Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 761-770	7.8	70
514	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. <i>Lancet Neurology</i> , 2017 , 16, 601-609	24.1	172

513	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 111-126	5.2	128
512	The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 767-775	4.3	4
511	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 387-393	4.3	8
510	The recency ratio is associated with reduced CSF glutamate in late-life depression. <i>Neurobiology of Learning and Memory</i> , 2017 , 141, 14-18	3.1	7
509	Alterations in the Balance of Amyloid- β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 1281-1291	4.3	4
508	Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2017 , 74, 557-566	17.2	435
507	Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer's Disease. <i>Stem Cell Reports</i> , 2017 , 8, 870-882	8	45
506	Clinical validity of cerebrospinal fluid A β 2, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017 , 52, 196-213	5.6	73
505	Histology-Compatible MALDI Mass Spectrometry Based Imaging of Neuronal Lipids for Subsequent Immunofluorescent Staining. <i>Analytical Chemistry</i> , 2017 , 89, 4685-4694	7.8	39
504	The Effects of Gene Mutations on 'Default' Mode Network in 'Familial' Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 327-334	4.3	7
503	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017 , 13, 274-284	1.2	91
502	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017 , 13, 285-295	1.2	88
501	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. <i>Neurobiology of Aging</i> , 2017 , 51, 104-112	5.6	115
500	Expanding the cerebrospinal fluid endopeptidome. <i>Proteomics</i> , 2017 , 17, 1600384	4.8	23
499	Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry. <i>ACS Chemical Neuroscience</i> , 2017 , 8, 347-355	5.7	46
498	Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. <i>Neurology</i> , 2017 , 89, 2167-2175	6.5	154
497	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. <i>Neurology</i> , 2017 , 89, 2230-2237	6.5	205
496	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , 2017 , 16, 965-975	24.1	118

495	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. <i>Proteomics - Clinical Applications</i> , 2017 , 11, 1700100	3.1	19
494	Earliest accumulation of β amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017 , 8, 1214	17.4	348
493	Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice. <i>Scientific Reports</i> , 2017 , 7, 14114	4.9	27
492	Serum tau and neurological outcome in cardiac arrest. <i>Annals of Neurology</i> , 2017 , 82, 665-675	9.4	55
491	Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. <i>Expert Review of Proteomics</i> , 2017 , 14, 1007-1020	4.2	16
490	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 1327-1334	4.3	28
489	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017 , 7, 13333	4.9	33
488	Gut microbiome alterations in Alzheimer's disease. <i>Scientific Reports</i> , 2017 , 7, 13537	4.9	712
487	Microstructural white matter alterations in preclinical Alzheimer's disease detected using free water elimination diffusion tensor imaging. <i>PLoS ONE</i> , 2017 , 12, e0173982	3.7	71
486	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 201-210	4.3	6
485	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. <i>BMC Neurology</i> , 2017 , 17, 170	3.1	44
484	Effects of surgery and propofol-remifentanyl total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer's disease, and neuronal injury in humans: a cohort study. <i>Journal of Neuroinflammation</i> , 2017 , 14, 193	10.1	9
483	Preclinical effects of APOE ϵ 4 on cerebrospinal fluid A β 2 concentrations. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 87	9	16
482	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 95	9	243
481	Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 243-252	4.3	8
480	Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017 , 7, 374-385	2.5	20
479	Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. <i>Journal of Neuroimmunology</i> , 2017 , 312, 15-18	3.5	39
478	A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. <i>Neurology and Therapy</i> , 2017 , 6, 15-24	4.6	141

477	Alzheimer's disease markers in the aged sheep (<i>Ovis aries</i>). <i>Neurobiology of Aging</i> , 2017 , 58, 112-119	5.6	17
476	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. <i>Neurobiology of Aging</i> , 2017 , 59, 1-9	5.6	52
475	F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1212-1223	12	124
474	Absolute Quantification of A β -42 in CSF Using a Mass Spectrometric Reference Measurement Procedure. <i>Journal of Visualized Experiments</i> , 2017 ,	1.6	3
473	Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. <i>European Journal of Neurology</i> , 2017 , 24, 1326-e77	6	55
472	[P3073]: EFFECTS OF RISPERIDONE AND GALANTAMINE TREATMENT ON ALZHEIMER BIOMARKER LEVELS IN CEREBROSPINAL FLUID 2017 , 13, P1047-P1048		
471	Low-dose B-secretase inhibition increases secretion of A β peptides and intracellular oligomeric A β <i>Molecular and Cellular Neurosciences</i> , 2017 , 85, 211-219	4.8	5
470	[P2041]: TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/A β PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF APP 2017 , 13, P661-P662		
469	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis. <i>BMJ Open</i> , 2017 , 7, e018177	3	3
468	[P2B67]: CROSS-SECTIONAL CORRELATION BETWEEN GTP1-TAU-PET AND CSF TAU AS MEASURES OF TAU BURDEN IN ALZHEIMER'S DISEASE 2017 , 13, P766-P766		
467	Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 1017-1026	4.3	17
466	Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 13018-13023	11.5	114
465	Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression. <i>Journal of Neural Transmission</i> , 2017 , 124, 1641-1645	4.3	3
464	[P4082]: A NEUROBIOLOGICAL MODEL OF MEMORY IMPAIRMENT IN LATE-LIFE MAJOR DEPRESSIVE DISORDER 2017 , 13, P1332-P1333		1
463	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , 2017 , 16, 661-676	24.1	308
462	Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. <i>Neurology</i> , 2017 , 89, 445-453	6.5	108
461	Ex vivo O-labeling mass spectrometry identifies a peripheral amyloid clearance pathway. <i>Molecular Neurodegeneration</i> , 2017 , 12, 18	19	15
460	Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls. <i>Journal of Neural Transmission</i> , 2017 , 124, 1135-1143	4.3	14

459	The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). <i>Virus Research</i> , 2017 , 227, 220-230	6.4	14
458	Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2017 , 74, 41-49	17.2	89
457	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. <i>Journal of Neurochemistry</i> , 2017 , 141, 296-304	6	87
456	Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study. <i>Journal of Neurotrauma</i> , 2017 , 34, 1124-1127	5.4	75
455	CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. <i>Neurobiology of Aging</i> , 2017 , 49, 138-144	5.6	46
454	Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. <i>European Journal of Neurology</i> , 2017 , 24, 112-121	6	23
453	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. <i>Alzheimer's and Dementia</i> , 2017 , 13, 59-71	1.2	70
452	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2017 , 19, 154-160	4.6	10
451	Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-infected individuals. <i>Journal of Neurovirology</i> , 2017 , 23, 106-112	3.9	15
450	The ACE Gene Is Associated with Late-Life Major Depression and Age at Dementia Onset in a Population-Based Cohort. <i>American Journal of Geriatric Psychiatry</i> , 2017 , 25, 170-177	6.5	9
449	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. <i>JAMA Neurology</i> , 2017 , 74, 1492-1501	17.2	67
448	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- β Concentration. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 885-891	4.3	5
447	[P1021]: EXPRESSION AND SECRETION OF SYNAPTIC PROTEINS DURING DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO CORTICAL NEURONS 2017 , 13, P328-P328		
446	[P1028]: DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKER-GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER'S DISEASE 2017 , 13, P243-P244		
445	[P2036]: THE PREVALENCE OF PRECLINICAL ALZHEIMER'S DISEASE IN A POPULATION STUDY OF 70-YEAR-OLDS 2017 , 13, P848-P848		1
444	[P3084]: N-TERMINAL FRAGMENT OF TAU: ASSAY DEVELOPMENT WITH IN-HOUSE CLEAVAGE-SPECIFIC ANTIBODY 2017 , 13, P964-P964		
443	[P3032]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY 2017 , 13, P985-P985		
442	[P3071]: ACUTE, TRANSIENT INCREASE IN SECRETION OF NEURODEGENERATION BIOMARKERS AFTER IRRADIATION OF HUMAN CORTICAL NEURONS 2017 , 13, P1000-P1000		

- 441 [P3174]: EFFECT OF PHYSICAL EXERCISE ON MARKERS OF NEURONAL DYSFUNCTION IN CEREBROSPINAL FLUID IN PATIENTS WITH ALZHEIMER'S DISEASE **2017**, 13, P1000-P1001
- 440 [P3198]: PREDICTION PERFORMANCE OF ALPHA-SYNUCLEIN PROTEIN IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY AD BIOMARKERS: THE INSIGHT-PRE AD STUDY **2017**, 13, P1011-P1011
- 439 [P3223]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLE-AGED ADULTS **2017**, 13, P1128-P1129
- 438 [P3225]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE **2017**, 13, P1130-P1130
- 437 [P4152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF AMYLOID (A β 2) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS **2017**, 13, P1316-P1317 1
- 436 [P4163]: STATISTICAL ALGORITHMS FOR HARMONIZING BIOMARKER DISTRIBUTIONS ACROSS DIFFERENT COHORTS, SITES AND ASSAYS: APPLICATIONS TO CSF MEASUREMENTS **2017**, 13, P1322-P1323
- 435 [P1150]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN IL1RAP AND ALZHEIMER'S-RELATED CSF-BIOMARKERS **2017**, 13, P300-P300
- 434 [IC-P-048]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE **2017**, 13, P41-P41
- 433 [IC-P-049]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLE-AGED ADULTS **2017**, 13, P41-P42
- 432 [P1187]: NOVEL METHOD FOR OLIGOMERIC A β DETECTION REVEALS INTRACELLULAR ACCUMULATION OF A β UPON LOW-DOSE TREATMENT WITH A GAMMA-SECRETASE INHIBITOR **2017**, 13, P314-P314
- 431 [P1268]: ANALYSIS OF NEW POTENTIAL CSF BIOMARKERS FOR ALZHEIMER'S DISEASE BY PARALLEL REACTION MONITORING MASS SPECTROMETRY **2017**, 13, P352-P352
- 430 [P1281]: DIAGNOSTIC PERFORMANCE USING CSF YKL-40 IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA **2017**, 13, P357-P358
- 429 [P1282]: DIAGNOSTIC ACCURACY OF CSF A β 1-42, P-TAU, T-TAU, NEUROFILAMENT LIGHT CHAIN, NEUROGRANIN, YKL-40 COMBINED BIOMARKERS IN A MULTICENTER COHORT OF COGNITIVELY IMPAIRED PATIENTS **2017**, 13, P358-P359
- 428 [P1287]: DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKER-GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER'S DISEASE **2017**, 13, P361-P361
- 427 [P1211]: LIFETIME PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF AMYLOID IN COGNITIVELY ASYMPTOMATIC APOE e4+ ADULTS **2017**, 13, P530-P531
- 426 [P2158]: IS THE PRESUBICULUM PROTECTED FROM NEURODEGENERATIVE CHANGES? A PATHOLOGICAL AND BIOCHEMICAL INVESTIGATION **2017**, 13, P668-P668
- 425 [P2208]: CSF AND PLASMA LEVELS OF INFLAMMATION DIFFERENTIALLY RELATE TO CNS MARKERS OF ALZHEIMER'S DISEASE PATHOLOGY AND NEURONAL DAMAGE **2017**, 13, P689-P689 0
- 424 [P2211]: AMYLOID- β 2 (A β 2) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID-POSITIVE VERSUS AMYLOID-NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT-RISK FOR AD POPULATION **2017**, 13, P690-P691

423 [P2041]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER'S DISEASE **2017**, 13, P703-P704

422 [P2046]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER'S DISEASE AND TAUOPATHIES **2017**, 13, P706-P707

421 [P2060]: TWO-LEVEL DIAGNOSTIC CLASSIFICATION USING CEREBROSPINAL FLUID NEUROGRANIN IN ALZHEIMER'S DISEASE **2017**, 13, P712-P713

420 [P2062]: ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN PROTEIN WITH BRAIN AMYLOID STATUS IN A PRECLINICAL COHORT OF SUBJECTIVE MEMORY COMPLAINERS: THE INSIGHT-PREAD STUDY **2017**, 13, P713-P714

419 [F30103]: THE PATHOGENIC BASIS OF THE ALZHEIMER CSF BIOMARKERS: WHAT DO WE KNOW TODAY? **2017**, 13, P878-P879

418 [O40201]: PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON'S AND ALZHEIMER'S DISEASE **2017**, 13, P1228

417 [O40204]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY **2017**, 13, P1230-P1231

416 [P4092]: NOVEL ASSAYS TO MONITOR A β PEPTIDES GENERATED BY THE ASPARAGATE ENDOPEPTIDASE AFTER INHIBITION OF BACE **2017**, 13, P1478

415 [P4070]: PRESYNAPTIC DEGRADATION IN ALZHEIMER'S DISEASE MEASURED BY NOVEL GAP-43 ELISA IN CSF **2017**, 13, P1513

414 [IC-P-171]: MODERATE INTENSITY PHYSICAL ACTIVITY ASSOCIATES WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE **2017**, 13, P128-P129

413 Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. *Journal of Visualized Experiments*, **2017**, 1.6 1

412 Factors Influencing Successful Lumbar Puncture in Alzheimer Research. *Alzheimer Disease and Associated Disorders*, **2017**, 31, 287-294 2.5 11

411 Mild traumatic brain injury is associated with increased levels of axonal injury biomarkers in blood. *British Journal of Sports Medicine*, **2017**, 51, A6.3-A7 10.3 1

410 [P3075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS **2017**, 13, P960-P961

409 High-throughput analysis of sulfatides in cerebrospinal fluid using automated extraction and UPLC-MS/MS. *Journal of Lipid Research*, **2017**, 58, 1482-1489 6.3 10

408 Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?. *PLoS ONE*, **2017**, 12, e0172762 3.7 30

407 Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment. *PLoS ONE*, **2017**, 12, e0176760 3.7 9

406 Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid- β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2017**, 55, 473-484 4.3 60

405	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 159-170	4.3	19
404	Cerebrospinal Fluid A β _{2/40} Corresponds Better than A β ₂ to Amyloid PET in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 813-822	4.3	120
403	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 19-35	4.3	29
402	Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 303-313	4.3	24
401	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 1489-1496	4.3	12
400	Preclinical Amyloid- β and Axonal Degeneration Pathology in Delirium. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 371-379	4.3	22
399	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016 , 12, 154-163	1.2	129
398	Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus. <i>Fluids and Barriers of the CNS</i> , 2016 , 13, 13	7	29
397	Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in <i>Drosophila melanogaster</i> . <i>FEBS Journal</i> , 2016 , 283, 3508-3522	5.7	8
396	Reference measurement procedure for CSF amyloid beta (A β) and the CSF A β /A β ₄₂ ratio - a cross-validation study against amyloid PET. <i>Journal of Neurochemistry</i> , 2016 , 139, 651-658	6	56
395	Calcium supplementation and risk of dementia in women with cerebrovascular disease. <i>Neurology</i> , 2016 , 87, 1674-1680	6.5	23
394	Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. <i>Journal of Neural Transmission</i> , 2016 , 123, 1443-1447	4.3	31
393	Plasma β amyloid in Alzheimer's disease and vascular disease. <i>Scientific Reports</i> , 2016 , 6, 26801	4.9	290
392	Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016 , 3, e271	9.1	82
391	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016 , 52, 51-64	4.3	17
390	Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 3, 98-102	5.2	47
389	Fluid biomarkers for mild traumatic brain injury and related conditions. <i>Nature Reviews Neurology</i> , 2016 , 12, 563-74	15	150
388	Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. <i>Neurology</i> , 2016 , 87, 1329-36	6.5	255

387	The clinical value of fluid biomarkers for dementia diagnosis - Authors' reply. <i>Lancet Neurology, The</i> , 2016 , 15, 1204-1205	24.1	5
386	O2-10-05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease 2016 , 12, P252-P252		
385	Traumatic brain injuries. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16084	51.1	245
384	Increased amyloidogenic APP processing in APOE e4-negative individuals with cerebral β amyloidosis. <i>Nature Communications</i> , 2016 , 7, 10918	17.4	39
383	Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation. <i>Scientific Reports</i> , 2016 , 6, 29200	4.9	41
382	Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. <i>Scientific Reports</i> , 2016 , 6, 36791	4.9	186
381	Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects. <i>Sleep</i> , 2016 , 39, 1253-60	1.1	35
380	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016 , 6, 283-94	2.5	23
379	High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 22	9	26
378	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid $A\beta$ 2 Levels in Cognitively Normal Elderly. <i>Sleep</i> , 2016 , 39, 2041-2048	1.1	92
377	No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. <i>Molecular Neurodegeneration</i> , 2016 , 11, 65	19	13
376	Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice. <i>Movement Disorders</i> , 2016 , 31, 836-47	7	38
375	Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. <i>European Journal of Neurology</i> , 2016 , 23, 796-806	6	35
374	APOE ϵ carriers may undergo synaptic damage conferring risk of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 1159-1166	1.2	21
373	Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. <i>Brain</i> , 2016 , 139, 2261-74	11.2	27
372	Cerebrospinal fluid ratios with $A\beta$ 2 predict preclinical brain β amyloid accumulation. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 2, 27-38	5.2	35
371	Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. <i>Clinical Proteomics</i> , 2016 , 13, 4	5	18
370	Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke. <i>Stroke</i> , 2016 , 47, 1943-5	6.7	73

369	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016 , 11, 3	19	168
368	Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players. <i>Journal of Neurotrauma</i> , 2016 , 33, 1995-1999	5.4	56
367	Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> , 2016 , 86, 829-35	6.5	135
366	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1587-1595	5	53
365	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016 , 12, 292-323	1.2	832
364	CSF A β 2/A β 0 and A β 2/A β 8 ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 154-65	5.3	244
363	CACNA1C polymorphism and altered phosphorylation of tau in bipolar disorder. <i>British Journal of Psychiatry</i> , 2016 , 208, 195-6	5.4	10
362	Alzheimer's disease. <i>Lancet, The</i> , 2016 , 388, 505-17	40	1720
361	Identification of tissue-specific cell death using methylation patterns of circulating DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E1826-34	11.5	350
360	A single dose of the β secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 11	9	12
359	YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016 , 292, 52-7	3.5	43
358	Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair. <i>Neurochemistry International</i> , 2016 , 93, 1-5	4.4	11
357	Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. <i>EBioMedicine</i> , 2016 , 3, 135-140	8.8	257
356	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β amyloid (1-42) in human cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2016 , 12, 517-26 ^{1,2}	1.2	179
355	Round robin test on quantification of amyloid- β 1-42 in cerebrospinal fluid by mass spectrometry. <i>Alzheimer's and Dementia</i> , 2016 , 12, 55-9	1.2	38
354	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. <i>JAMA Neurology</i> , 2016 , 73, 60-7	17.2	258
353	Assessing the commutability of reference material formats for the harmonization of amyloid- β measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016 , 54, 1177-91	5.9	48
352	Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 93-100	4.3	25

351	Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 733-41	4.3	15
350	C3 deficiency ameliorates the negative effects of irradiation of the young brain on hippocampal development and learning. <i>Oncotarget</i> , 2016 , 7, 19382-94	3.3	10
349	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. <i>Journal of Alzheimer's Disease</i> , 2016 , 52, 1373-83	4.3	37
348	A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 53, 1353-63	4.3	19
347	Association between Genotype and Change in Physical Function in a Population-Based Swedish Cohort of Older Individuals Followed Over Four Years. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 225	5.3	9
346	Blood biomarkers indicate mild neuroaxonal injury and increased amyloid β production after transient hypoxia during breath-hold diving. <i>Brain Injury</i> , 2016 , 30, 1226-30	2.1	17
345	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016 , 87, 539-47	6.5	710
344	Update on fluid biomarkers for concussion. <i>Concussion</i> , 2016 , 1, CNC12	1.8	4
343	Apolipoprotein E polymorphism in aneurysmal subarachnoid haemorrhage in West Sweden. <i>Acta Neurologica Scandinavica</i> , 2016 , 133, 466-74	3.8	12
342	Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 30	9	82
341	Cerebrospinal fluid levels of insulin, leptin, and agouti-related protein in relation to BMI in pregnant women. <i>Obesity</i> , 2016 , 24, 1299-304	8	7
340	Cerebral white matter lesions - associations with A β isoforms and amyloid PET. <i>Scientific Reports</i> , 2016 , 6, 20709	4.9	41
339	Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 1395-1408	4.3	29
338	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2016 , 8, 1184-1196	12	152
337	Serum erythropoietin and outcome after ischaemic stroke: a prospective study. <i>BMJ Open</i> , 2016 , 6, e009327	6	6
336	sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016 , 8, 466-76	12	256
335	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 41	9	78
334	Specific Triazine Herbicides Induce Amyloid- β Production. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 1593-1605	4.3	11

- 333 D2 Cerebrospinal fluid biomarkers in huntington's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A34.2-A34 5.5
- 332 P3-129: Psychological Stress in Midlife Associated with Higher Levels of CSF T-TAU and AB40 in Late-Life: A 25-YEAR Longitudinal Population Study of Women **2016**, 12, P869-P869
- 331 O1-05-01: Increased Amyloidogenic app Processing in Apoe E4-Negative Individuals with Cerebral B-Amyloidosis **2016**, 12, P182-P182
- 330 O5-01-02: Stress is Associated with Greater Insulin Resistance, Higher CSF Phosphorylated TAU, and Decreased Glucose Metabolism in the Medial Temporal Lobe in apoe ϵ Carriers **2016**, 12, P375-P376
- 329 P1-172: Combined Added Value of Cerebrospinal Fluid Neurogranin and Neurofilament Light Chain Protein in the Diagnosis and Classification Of Prodromal and Alzheimer's Disease Dementia **2016**, 12, P468-P469
- 328 IC-P-050: MCI Status, Amyloid and TAU Biomarkers, and Composite Cognitive Impairment Scores are Associated with Cogstate Performance in The Wisconsin Registry For Alzheimer's Prevention **2016**, 12, P41-P42
- 327 P1-322: Four-Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and are Associated with CSF Biomarkers in Patients with MCI **2016**, 12, P548-P549
- 326 P1-344: Poor Sleep Quality is Associated with CSF Markers of Amyloid Deposition in Cognitively Healthy Adults at Risk for Alzheimer's Disease **2016**, 12, P561-P561
- 325 P1-410: Lifetime Recreational Physical Activity is Associated with CSF Amyloid in Cognitively Asymptomatic Adults **2016**, 12, P591-P592
- 324 P2-151: Cerebrospinal Fluid Biomarker Profile of Amyloid, TAU, Synaptic, Microglial, and Lysosomal Pathophysiology in Cognitively Normal Preclinical Individuals Stratified by Amyloid-Pet Status **2016**, 12, P672-P672
- 323 P2-152: Characterization of the Postsynaptic Protein Neurogranin in Different Brain Regions in Patients with Familial Alzheimer's Disease, Alzheimer's Disease, Pathological Aging And Healthy Controls **2016**, 12, P672-P672
- 322 P2-142: Comparison of T-Tau, Neurogranin and NFL as CSF Neurodegeneration Markers in Alzheimer's Disease **2016**, 12, P667-P667
- 321 IC-P-123: Four Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and Are Associated With CSF Biomarkers in Patients With MCI **2016**, 12, P91-P92
- 320 P2-430: The Prevalence of Pathological CSF Abeta-42 and ITS Relation to Education in a Population Sample of Older People from Sweden **2016**, 12, P810-P810
- 319 P3-162: Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Chain Protein in the Classification of Prodromal and Alzheimer's Disease Dementia **2016**, 12, P881-P881 1
- 318 P3-165: Plasma Biomarker Profile of Amyloid, TAU, and Neuronal Pathophysiology in Cognitively Normal Preclinical Individuals Stratified by Amyloid-Pet Status **2016**, 12, P882-P883
- 317 P3-193: Serum Neurofilament Light Protein Predicts Clinical Outcome in Traumatic Brain Injury **2016**, 12, P896-P897
- 316 P4-114: Cerebrospinal Fluid Biomarkers of Neuronal Injury in Chronic Traumatic Brain Injury **2016**, 12, P1056-P1056

- 315 FTS3-01-03: Biomarkers for Vascular Contributions to Dementia **2016**, 12, P276-P277
- 314 O1-05-06: Stability of Amyloid-Beta (A β 2) in Fresh Versus Frozen Human Cerebrospinal Fluid Samples as Measured with the Elecsys β B-Amyloid(A β 2) Immunoassay **2016**, 12, P185-P185
- 313 O1-10-01: Gantenerumab Treatment Reduces Biomarkers of Neuronal and Synaptic Degeneration in Alzheimer's Disease **2016**, 12, P198-P198 2
- 312 O1-11-05: CSF In the Differential Diagnosis of Alzheimer's Disease: Clinical Utility of an Extended Panel Of Biomarkers in a Specialist Cognitive Clinic **2016**, 12, P203-P204 1
- 311 O3-03-02: MCI STATUS, AMYLOID AND TAU BIOMARKERS, AND COMPOSITE COGNITIVE IMPAIRMENT SCORES ARE ASSOCIATED WITH COGSTATE PERFORMANCE IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION **2016**, 12, P285-P286
- 310 O3-09-01: Distinct Cognitive Trajectories in Late Middle-Age and their Associations with Brain Structure and Alzheimer's Disease Biomarkers: Findings from the Wisconsin Registry for Alzheimer's Prevention **2016**, 12, P306-P307
- 309 O4-10-01: PLASMA NFL: A NEW BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN DISORDERS **2016**, 12, P357-P357
- 308 P1-012: A Population-Based Study on the Relation Between Sleep Disturbance and Beta-Amyloid 42 in Cerebrospinal Fluid in 70-Year-Olds **2016**, 12, P404-P404
- 307 P1-028: Does Calcium Supplementation Increase the Risk of Dementia in Women With Cerebrovascular Disease? A Five Year Follow-Up of Older Swedish Women **2016**, 12, P412-P412
- 306 P1-171: Added Diagnostic Value of Cerebrospinal Fluid Neurogranin in the Classification of Prodromal and Alzheimer's Disease Dementia **2016**, 12, P468-P468
- 305 P1-177: How Accurate are Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease? A Systematic Review **2016**, 12, P471-P472
- 304 P1-181: State-Dependent Alterations in CSF A β 2 Levels in Cognitively-Intact Elderly With Late Life Major Depression **2016**, 12, P473-P474
- 303 P1-197: EvaluationTM, A Novel Multiplex Technology for Simultaneous Quantification of Inflammation Markers, A β Amyloid and TAU Proteins **2016**, 12, P479-P479
- 302 P1-204: Neurogranin: a Specific Synaptic Biomarker for Amnesic Alzheimer's Disease? **2016**, 12, P483-P483
- 301 P4-312: Progress on the Development of Certified Reference Materials for AB1-42 **2016**, 12, P1153-P1153
- 300 P4-313: Commutability of the Candidate Certified Reference Materials for the Standardization of A β -42 Measurements in Human Cerebrospinal Fluid **2016**, 12, P1153-P1154
- 299 P4-324: Plasma Neurofilament Light Concentration Predicts Long-Term Outcome an Acute Stroke **2016**, 12, P1158-P1158
- 298 Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2016**, 50, 873-86 4-3 75

297	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. <i>Scientific Reports</i> , 2016 , 6, 38737	4.9	64
296	Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. <i>Translational Psychiatry</i> , 2016 , 6, e744	8.6	45
295	Serum Neurofilament Light in American Football Athletes over the Course of a Season. <i>Journal of Neurotrauma</i> , 2016 , 33, 1784-1789	5.4	78
294	Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. <i>Neurology</i> , 2016 , 86, 1754-61	6.5	48
293	CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. <i>Lancet Neurology</i> , 2016 , 15, 673-684	24.1	979
292	Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016 , 54, 1655-61	5.9	329
291	Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016 , 299, 112-117	3.5	30
290	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. <i>Proteomics - Clinical Applications</i> , 2016 , 10, 1242-1253	3.1	40
289	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β in a multicentre European memory clinic study. <i>Brain</i> , 2016 , 139, 2540-53	11.2	93
288	Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. <i>JAMA Neurology</i> , 2016 , 73, 1308-1315	15.2	75
287	Plasma tau in Alzheimer disease. <i>Neurology</i> , 2016 , 87, 1827-1835	6.5	269
286	Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ϵ allele. <i>Brain Research</i> , 2016 , 1651, 11-16	3.7	20
285	Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 12-20	5.3	115
284	Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 216-25	5.3	124
283	Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease. <i>Movement Disorders</i> , 2016 , 31, 898-905	7	94
282	The distribution of apolipoprotein E genotype over the adult lifespan and in relation to country of birth. <i>American Journal of Epidemiology</i> , 2015 , 181, 214-7	3.8	19
281	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1316-28	1.2	41
280	Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. <i>Nature Medicine</i> , 2015 , 21, 217-9	50.5	52

279	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1180-90	1.2	201
278	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015 , 11, 772-91	1.2	53
277	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015 , 138, 2701-15.2	15.2	86
276	Cerebrospinal fluid tau and amyloid- β 42 in patients with dementia. <i>Brain</i> , 2015 , 138, 2716-31	11.2	105
275	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015 , 36, 2587-96	5.6	29
274	Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. <i>Clinica Chimica Acta</i> , 2015 , 449, 9-15	6.2	51
273	Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1470-1479	1.2	12
272	APP metabolism regulates tau proteostasis in human cerebral cortex neurons. <i>Cell Reports</i> , 2015 , 11, 689-96	10.6	137
271	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
270	Laboratory testing for lyme neuroborreliosis. <i>JAMA Neurology</i> , 2015 , 72, 125-6	17.2	1
269	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1306-15	1.2	87
268	Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 550-61	5	92
267	Amyloid biomarkers in Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 297-309	13.2	320
266	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. <i>Journal of Neurology</i> , 2015 , 262, 2722-30	5.5	34
265	Protective properties of lysozyme on β amyloid pathology: implications for Alzheimer disease. <i>Neurobiology of Disease</i> , 2015 , 83, 122-33	7.5	47
264	Increased CSF biomarkers of angiogenesis in Parkinson disease. <i>Neurology</i> , 2015 , 85, 1834-42	6.5	75
263	Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. <i>JAMA Neurology</i> , 2015 , 72, 1175-82	17.2	111
262	The relationship between CSF tau markers, hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 81-86	5.2	4

261	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 40	9	90
260	C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1461-1469	1.2	95
259	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , 2015 , 85, 1240-9	6.5	192
258	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. <i>Brain</i> , 2015 , 138, 3373-85	11.2	165
257	Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 2015 , 609, 58-62	3.3	13
256	A 9-year prospective population-based study on the association between the APOE*E4 allele and late-life depression in Sweden. <i>Biological Psychiatry</i> , 2015 , 78, 730-6	7.9	58
255	Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. <i>Brain, Behavior, and Immunity</i> , 2015 , 43, 198-204	16.6	44
254	Serum SNTF Increases in Concussed Professional Ice Hockey Players and Relates to the Severity of Postconcussion Symptoms. <i>Journal of Neurotrauma</i> , 2015 , 32, 1294-300	5.4	80
253	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 455-61	1.2	7
252	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 58-69	1.2	271
251	Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor. <i>Journal of Alzheimer's Disease</i> , 2015 , 43, 1059-72	4.3	60
250	Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 43, 1393-402	4.3	20
249	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. <i>Journal of the International Neuropsychological Society</i> , 2015 , 21, 841-50	3.1	37
248	P4-004: Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer's disease 2015 , 11, P766-P766		1
247	P2-063: A β 0 and A β 2 levels in plasma: Comparison of enzyme-linked immunosorbent assay (ELISA) with multiplex technology 2015 , 11, P507-P507		
246	Intracranial Arterial 4D-Flow is Associated with Metrics of Brain Health and Alzheimer's Disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 420-428	5.2	21
245	P1-316: The role of lysozyme in Alzheimer's disease 2015 , 11, P477-P478		5
244	P3-103: Assessing the significance of insulin resistance on cerebrospinal fluid Alzheimer's disease biomarkers and memory function in people at risk for Alzheimer's disease: Findings from the wisconsin adrc impact cohort 2015 , 11, P659-P660		

243	P1-069: Moderate-to-high intensity physical training does not alter cerebrospinal amyloid- β -42 levels in patients with Alzheimer's disease 2015 , 11, P364-P365		
242	P1-204: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy ApoE ϵ carriers 2015 , 11, P427-P428		
241	Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15056	51.1	755
240	Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 1313-22	4.3	19
239	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015 , 48 Suppl 1, S171-91	4.3	29
238	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid- β Levels in Patients with Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 1069-78	4.3	21
237	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 291-317	4.3	61
236	37 Years of Body Mass Index and Dementia: Effect Modification by the APOE Genotype: Observations from the Prospective Population Study of Women in Gothenburg, Sweden. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 1119-27	4.3	17
235	Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 637-46	4.3	22
234	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 403-11	5.2	16
233	P4-038: Factors influencing lumbar puncture participation in Alzheimer's research 2015 , 11, P780-P780		2
232	P1-099: White matter lesions but not lacunes are associated with the CSF levels of A β 8 and A β 0, and to a lesser degree with CSF A β 2 2015 , 11, P376-P377		
231	P2-062: Are cerebrospinal fluid levels of neurogranin associated with hippocampal atrophy and brain white matter volume decrease? 2015 , 11, P506-P507		
230	APLP1 as a cerebrospinal fluid biomarker for β -secretase modulator treatment. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 77	9	8
229	Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with A β 2 and influence of disease on the total-A β 2/A β 0 ratio. <i>Journal of Neurochemistry</i> , 2015 , 135, 1049-58	6	14
228	Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 74	9	86
227	Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOE ϵ 4 Carriers. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 525-33	4.3	48
226	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 661-7	4.3	10

225	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , 2015 , 6, 179	4.1	223
224	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015 , 6, 216	4.1	31
223	The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. <i>Frontiers in Neuroscience</i> , 2015 , 9, 345	5.1	58
222	Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls. <i>PLoS ONE</i> , 2015 , 10, e0127100	3.7	21
221	Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2015 , 40, 250-8	4.5	59
220	First effects of rising amyloid- β in transgenic mouse brain: synaptic transmission and gene expression. <i>Brain</i> , 2015 , 138, 1992-2004	11.2	49
219	Rarity of the Alzheimer disease-protective APP A673T variant in the United States. <i>JAMA Neurology</i> , 2015 , 72, 209-16	17.2	31
218	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015 , 11, 549-60	1.2	159
217	CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. <i>European Neuropsychopharmacology</i> , 2015 , 25, 1091-8	1.2	40
216	P4-066: The relationship between intracranial vascular health and metrics of Alzheimer's disease 2015 , 11, P793-P794		
215	P1-010: Quantification of the synaptic protein neurogranin in cerebrospinal fluid across different neurodegenerative diseases: A selective Alzheimer's disease biomarker? 2015 , 11, P340-P340		
214	P1-110: Predictors of cognitive decline in elderly depressives 2015 , 11, P381-P382		
213	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions 2015 , 11, P384-P384		1
212	P1-116: Correlation of the modified innotest β amyloid 1-42 with a lc-ms/ms candidate reference method 2015 , 11, P385-P385		1
211	P2-074: Differences in the TREM2 levels in the CSF of Alzheimer's disease cases and controls 2015 , 11, P511-P511		
210	P4-036: CSF Alzheimer's disease-related biomarkers are higher in subjects with periodontal disease 2015 , 11, P779-P779		
209	P1-033: A candidate reference method for analysis of amyloid beta 1-42 (A β -42) peptide in human CSF using 2D-HPLC with a xevo t q-s mass spectrometer 2015 , 11, P349-P349		
208	Independent information from cerebrospinal fluid amyloid- β and florbetapir imaging in Alzheimer's disease. <i>Brain</i> , 2015 , 138, 772-83	11.2	169

207	Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria. <i>Clinica Chimica Acta</i> , 2015 , 449, 3-8	6.2	22
206	White matter changes in familial Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2015 , 278, 211-8	10.8	20
205	Fluid markers of traumatic brain injury. <i>Molecular and Cellular Neurosciences</i> , 2015 , 66, 99-102	4.8	35
204	A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. <i>Neuropsychologia</i> , 2015 , 69, 1-8	3.2	16
203	Explorative and targeted neuroproteomics in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015 , 1854, 769-78	4	36
202	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 1240-7	5.5	151
201	Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. <i>journal of prevention of Alzheimer's disease, The</i> , 2015 , 2, 128-135	3.8	24
200	Amyloid and Tau Biomarkers in CSF. <i>journal of prevention of Alzheimer's disease, The</i> , 2015 , 2, 46-50	3.8	2
199	Cerebrospinal fluid markers of central nervous system injury in decompression illness - a case-controlled pilot study. <i>Diving and Hyperbaric Medicine</i> , 2015 , 45, 240-3	1	4
198	Cerebrospinal fluid biomarkers in cardiac arrest survivors. <i>Resuscitation</i> , 2014 , 85, 227-32	4	19
197	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology, The</i> , 2014 , 13, 614-29	24.1	1985
196	Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. <i>New England Journal of Medicine</i> , 2014 , 370, 322-33	59.2	1274
195	CSF A β -42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 381-92	1.2	53
194	Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients. <i>Neuropsychopharmacology</i> , 2014 , 39, 2349-56	8.7	50
193	CSF A β 2 predicts early-onset dementia in Parkinson disease. <i>Neurology</i> , 2014 , 82, 1784-90	6.5	108
192	Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid- β in cerebrospinal fluid. <i>Clinical Chemistry</i> , 2014 , 60, 987-94	5.5	109
191	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014 , 10, 808-17	1.2	132
190	Performance on a pattern separation task by Alzheimer's patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ϵ 4 status and cerebrospinal fluid amyloid- β 2 levels. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 20	9	39

189	Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down's syndrome. <i>NeuroMolecular Medicine</i> , 2014 , 16, 510-6	4.6	26
188	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014 , 10, 713-723.e2	1.2	204
187	Automated cerebrospinal fluid cell count--new reference ranges and evaluation of its clinical use in central nervous system infections. <i>Clinical Biochemistry</i> , 2014 , 47, 25-30	3.5	21
186	Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. <i>Neurobiology of Aging</i> , 2014 , 35, 1318-24	5.6	83
185	Imatinib treatment and A β 2 in humans. <i>Alzheimer's and Dementia</i> , 2014 , 10, S374-80	1.2	10
184	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014 , 88, 426-49	6	84
183	Levels of cerebrospinal fluid β synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 25	9	130
182	Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. <i>Brain, Behavior, and Immunity</i> , 2014 , 41, 55-8	16.6	61
181	Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. <i>Psychiatry Research</i> , 2014 , 217, 143-6	9.9	32
180	Cerebrospinal fluid sphingolipids, β amyloid, and tau in adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014 , 35, 2486-2494	5.6	45
179	CSF biomarkers for Alzheimer's pathology and the effect size of APOE e4. <i>Molecular Psychiatry</i> , 2014 , 19, 148-9	15.1	26
178	Agitation in dementia: relation to core cerebrospinal fluid biomarker levels. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 335-43	2.5	25
177	Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. <i>Journal of Central Nervous System Disease</i> , 2014 , 6, 51-8	4.4	67
176	Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain. <i>Journal of Alzheimer's Disease</i> , 2014 , 39, 719-26	4.3	44
175	P4-049: IMPACT OF READY TO USE CALIBRATORS AND THE USE OF UNIFIED STANDARD OPERATING PROCEDURES ON THE VARIABILITY IN ASSAY PERFORMANCE 2014 , 10, P800-P800		
174	P2-110: ELEVATED CEREBROSPINAL FLUID LEVELS OF NEUROGRANIN IN ALZHEIMER'S DISEASE 2014 , 10, P511-P511		
173	P3-103: INCREASED LEVELS OF CEREBROSPINAL FLUID FATTY ACID BINDING PROTEIN 3 ARE RELATED TO DEMENTIA DEVELOPMENT IN A POPULATION-BASED SAMPLE OF ELDERLY WOMEN FOLLOWED FOR 8 YEARS 2014 , 10, P666-P666		
172	Neurological assessment and its relationship to CSF biomarkers in amateur boxers. <i>PLoS ONE</i> , 2014 , 9, e99870	3.7	23

171	Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 385-94	2.5	24
170	Targeting synaptic pathology with a novel affinity mass spectrometry approach. <i>Molecular and Cellular Proteomics</i> , 2014 , 13, 2584-92	7.6	22
169	Bite amyloid precursor protein-cleaving enzyme 1 (BACE1) inhibitor treatment induces A β -X peptides through alternative amyloid precursor protein cleavage. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 75	9	28
168	Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. <i>Translational Psychiatry</i> , 2014 , 4, e419	8.6	32
167	Comment on "An antidepressant decreases CSF A β production in healthy individuals and in transgenic AD mice". <i>Science Translational Medicine</i> , 2014 , 6, 268le5	17.5	4
166	Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 297-304	2.5	63
165	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014 , 1, 534-43	5.3	78
164	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014 , 9, 53	19	150
163	Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2014 , 4, 549-60	5.3	68
162	Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β amyloid 42: a cross-validation study against amyloid positron emission tomography. <i>JAMA Neurology</i> , 2014 , 71, 1282-9 ^{17.2}	17.2	254
161	Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. <i>JAMA Psychiatry</i> , 2014 , 71, 1183-91	14.5	65
160	Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. <i>JAMA Neurology</i> , 2014 , 71, 476-83 ^{17.2}	17.2	125
159	Tau, s-100 calcium-binding protein B, and neuron-specific enolase as biomarkers of concussion-reply. <i>JAMA Neurology</i> , 2014 , 71, 926-7	17.2	8
158	Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 877-86	4.3	21
157	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. <i>Neurology</i> , 2014 , 83, 1945-53	6.5	186
156	Blood biomarkers for brain injury in concussed professional ice hockey players. <i>JAMA Neurology</i> , 2014 , 71, 684-92	17.2	264
155	CSF levels of YKL-40 are increased in MS and reduces with immunosuppressive treatment. <i>Journal of Neuroimmunology</i> , 2014 , 269, 87-9	3.5	43
154	Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 607-14	4	14

153	The amyloid- β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease. <i>Neuroscience Letters</i> , 2014 , 573, 7-12	3.3	48
152	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 115-312		196
151	Biomarkers in amyloid- β immunotherapy trials in Alzheimer's disease. <i>Neuropsychopharmacology</i> , 2014 , 39, 189-201	8.7	54
150	The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. <i>Journal of prevention of Alzheimer's disease, The</i> , 2014 , 1, 181-202	3.8	39
149	Plasma tau levels in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 9	9	262
148	Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 2	9	12
147	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013 , 9, 251-61	1.2	289
146	Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. <i>Resuscitation</i> , 2013 , 84, 351-6	4	157
145	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. <i>Alzheimer's and Dementia</i> , 2013 , 9, 137-40	1.2	93
144	The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. <i>Medical Clinics of North America</i> , 2013 , 97, 369-76	7	47
143	Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. <i>Journal of Neurology</i> , 2013 , 260, 620-6	5.5	67
142	A selected reaction monitoring (SRM)-based method for absolute quantification of A β 8, A β 10, and A β 2 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 1021-32	4.3	86
141	Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. <i>Brain Injury</i> , 2013 , 27, 425-33	2.1	90
140	Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. <i>Neurology</i> , 2013 , 80, 1385-92	6.5	108
139	Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e76537	3.7	131
138	The neuropathology and neurobiology of traumatic brain injury. <i>Neuron</i> , 2012 , 76, 886-99	13.9	426
137	Fluid biomarkers in Alzheimer disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012 , 2, a006221	5.4	120
136	Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. <i>Archives of Neurology</i> , 2012 , 69, 1445-52		327

135	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β . <i>Biomarkers in Medicine</i> , 2012 , 6, 409-17	2.3	66
134	Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. <i>PLoS ONE</i> , 2012 , 7, e38639	3.7	56
133	An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid. <i>Journal of Mass Spectrometry</i> , 2012 , 47, 591-603	2.2	64
132	Cerebrospinal fluid levels of β amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. <i>Archives of General Psychiatry</i> , 2012 , 69, 98-106		459
131	SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration. <i>Journal of Proteomics</i> , 2011 , 75, 425-34	3.9	45
130	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011 , 7, 386-395.e6	1.2	291
129	Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid β levels in humans. <i>PLoS ONE</i> , 2011 , 6, e28263	3.7	117
128	Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. <i>Journal of Alzheimer's Disease</i> , 2011 , 24, 537-46	4.3	62
127	No neurochemical evidence of brain injury after blast overpressure by repeated explosions or firing heavy weapons. <i>Acta Neurologica Scandinavica</i> , 2011 , 123, 245-51	3.8	24
126	Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. <i>NeuroMolecular Medicine</i> , 2011 , 13, 151-9	4.6	89
125	Dementia in 2010: Paving the way for Alzheimer disease drug development. <i>Nature Reviews Neurology</i> , 2011 , 7, 65-6	15	6
124	Biomarkers in Alzheimer's disease drug development. <i>Nature Medicine</i> , 2010 , 16, 1218-22	50.5	102
123	Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. <i>International Journal of Alzheimer's Disease</i> , 2010 , 2010,	3.7	132
122	Evaluation of plasma A β (40) and A β (42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010 , 31, 357-67	5.6	197
121	The ACE Insertion Deletion polymorphism relates to dementia by metabolic phenotype, APOE ϵ 4, and age of dementia onset. <i>Neurobiology of Aging</i> , 2010 , 31, 910-6	5.6	19
120	Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010 , 6, 131-44	15	1328
119	CSF biomarkers predict a more malignant outcome in Alzheimer disease. <i>Neurology</i> , 2010 , 74, 1531-7	6.5	141
118	Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 1119-28	4.3	94

117	Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2010 , 120, 185-93	14.3	226
116	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. <i>Brain Research</i> , 2010 , 1362, 13-22	3.7	156
115	Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. <i>European Journal of Neurology</i> , 2010 , 17, 377-82	6	73
114	Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 27, 458-64	2.6	96
113	Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). <i>Experimental Gerontology</i> , 2009 , 44, 579-85	4.5	55
112	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. <i>Annals of Neurology</i> , 2009 , 65, 403-13	9.4	1502
111	Use of CSF biomarkers in Alzheimer's disease clinical trials. <i>Journal of Nutrition, Health and Aging</i> , 2009 , 13, 358-61	5.2	11
110	Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. <i>Journal of Nutrition, Health and Aging</i> , 2009 , 13, 205-8	5.2	37
109	The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009 , 30, 672-81	5.6	65
108	Transient inflammation in neurogenic regions after irradiation of the developing brain. <i>Radiation Research</i> , 2009 , 171, 66-76	3.1	68
107	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 385-93	27.4	758
106	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. <i>Lancet Neurology</i> , 2009 , 8, 619-27	24.1	473
105	Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. <i>Archives of Neurology</i> , 2008 , 65, 1102-7		162
104	What is the future for CSF biomarkers in the prediction of cognitive decline and Alzheimer's disease?. <i>Aging Health</i> , 2008 , 4, 213-215		
103	Cystatin C in cerebrospinal fluid and multiple sclerosis. <i>Annals of Neurology</i> , 2007 , 62, 193-6; discussion 205	9.4	28
102	Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. <i>Nature Medicine</i> , 2007 , 13, 1359-62	50.5	813
101	Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. <i>European Journal of Neurology</i> , 2007 , 14, 1329-33	6	102
100	Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 461-4	5.5	150

99	Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 23, 316-20	2.6	204
98	Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 24, 118-24	2.6	120
97	Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. <i>Journal of Proteome Research</i> , 2007 , 6, 4433-9	5.6	113
96	Longitudinal stability of CSF biomarkers in Alzheimer's disease. <i>Neuroscience Letters</i> , 2007 , 419, 18-22	3.3	145
95	Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. <i>Lancet Neurology</i> , 2006 , 5, 228-34	24.1	1254
94	Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. <i>Neurology</i> , 2006 , 67, 1600-4	6.5	230
93	Neurochemical aftermath of amateur boxing. <i>Archives of Neurology</i> , 2006 , 63, 1277-80		256
92	Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006 , 44, 1472-80	5.9	100
91	Alzheimer's disease. <i>Lancet, The</i> , 2006 , 368, 387-403	40	2621
90	Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. <i>Journal of Proteome Research</i> , 2006 , 5, 1010-6	5.6	161
89	Neurochemical aftermath of amateur boxing. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2006 , 16, 470-470	4.6	
88	Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta 1-42 and plasma apolipoprotein levels. <i>Journal of Human Genetics</i> , 2006 , 51, 171-179	4.3	10
87	Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. <i>Clinical Chemistry</i> , 2005 , 51, 336-45	5.5	358
86	CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. <i>Expert Review of Molecular Diagnostics</i> , 2005 , 5, 661-72	3.8	99
85	The transcobalamin 776C > G polymorphism may be a modifiable genetic risk factor for Alzheimer's disease. <i>International Psychogeriatrics</i> , 2005 , 17, 329-31	3.4	2
84	Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. <i>International Journal of Molecular Medicine</i> , 2005 , 16, 1147-9	4.4	42
83	Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. <i>Archives of General Psychiatry</i> , 2004 , 61, 95-102		336
82	CSF biomarkers for mild cognitive impairment. <i>Journal of Internal Medicine</i> , 2004 , 256, 224-34	10.8	122

81	Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. <i>Journal of Internal Medicine</i> , 2004 , 256, 240-6	10.8	3289
80	Cerebrospinal fluid protein biomarkers for Alzheimer's disease. <i>NeuroRx</i> , 2004 , 1, 213-25		353
79	Cerebrospinal fluid protein biomarkers for Alzheimer's disease. <i>Neurotherapeutics</i> , 2004 , 1, 213-225	6.4	
78	An 18-year follow-up of overweight and risk of Alzheimer disease. <i>Archives of Internal Medicine</i> , 2003 , 163, 1524-8		537
77	Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003 , 15, 169-76	2.6	138
76	CSF markers for incipient Alzheimer's disease. <i>Lancet Neurology</i> , 2003 , 2, 605-13	24.1	969
75	Lipid analyses of human brain rafts. <i>Journal of Neurochemistry</i> , 2003 , 85, 34-34	6	3
74	CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. <i>Neurology</i> , 2003 , 60, 652-6	6.5	444
73	CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. <i>Brain Research Bulletin</i> , 2003 , 61, 235-42	3.9	60
72	Reply to MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis. <i>European Journal of Human Genetics</i> , 2002 , 10, 579-582	5.3	7
71	Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. <i>Archives of Neurology</i> , 2002 , 59, 1267-72		225
70	CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. <i>Neurology</i> , 2002 , 59, 627-9	6.5	205
69	Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002 , 13, 112-8	2.6	110
68	The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001 , 12, 257-64	2.6	81
67	Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. <i>Journal of Neuroscience Research</i> , 2001 , 66, 510-6	4.4	142
66	Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. <i>Electrophoresis</i> , 2001 , 22, 1834-7	3.6	30
65	Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. <i>Proteomics</i> , 2001 , 1, 444-52	4.8	103
64	CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. <i>Molecular Neurobiology</i> , 2001 , 24, 87-97	6.2	186

63	Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. <i>European Journal of Human Genetics</i> , 2001 , 9, 437-44	5.3	132
62	Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. <i>Archives of Neurology</i> , 2001 , 58, 373-9		372
61	Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. <i>Neuroscience Letters</i> , 2001 , 297, 187-90	3.3	347
60	Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. <i>Neurochemical Research</i> , 2000 , 25, 511-7.4.6		66
59	No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. <i>Journal of Neural Transmission</i> , 2000 , 107, 1065-79.4.3	4.3	88
58	Reduction of the synaptic protein rab3a in the thalamus and connecting brain regions in post-mortem schizophrenic brains. <i>Journal of Neural Transmission</i> , 2000 , 107, 1085-97	4.3	21
57	CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. <i>Journal of Neural Transmission</i> , 2000 , 107, 563-79	4.3	194
56	Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. <i>Journal of Alzheimer's Disease</i> , 2000 , 2, 199-206	4.3	160
55	Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. <i>Neuroscience Letters</i> , 2000 , 285, 49-52	3.3	397
54	Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000 , 7, 245-58	2.7	268
53	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Their Role in Clinical Chemistry. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2000 , 12, 11-20	2.4	
52	Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. <i>Archives of Neurology</i> , 1999 , 56, 673-80		518
51	Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. <i>Journal of Clinical Immunology</i> , 1999 , 19, 223-30	5.7	242
50	The growth-associated protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in schizophrenia. <i>Journal of Molecular Neuroscience</i> , 1999 , 13, 101-9	3.3	39
49	Identification of proteins in a human pleural exudate using two-dimensional preparative liquid-phase electrophoresis and matrix-assisted laser desorption/ionization mass spectrometry. <i>Electrophoresis</i> , 1999 , 20, 860-5	3.6	49
48	Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. <i>Electrophoresis</i> , 1999 , 20, 431-7	3.6	81
47	Removal of sodium dodecyl sulfate from protein samples prior to matrix-assisted laser desorption/ionization mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 1999 , 13, 344-9	2.2	84
46	Analysis of intact proteins from cerebrospinal fluid by matrix-assisted laser desorption/ionization mass spectrometry after two-dimensional liquid-phase electrophoresis. <i>Rapid Communications in Mass Spectrometry</i> , 1999 , 13, 2450-5	2.2	15

45	Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. <i>Neuroscience Letters</i> , 1999 , 273, 5-8	3.3	205
44	Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 1998 , 19, 379-84	5.6	68
43	Neurochemical dissection of synaptic pathology in Alzheimer's disease. <i>International Psychogeriatrics</i> , 1998 , 10, 11-23	3.4	136
42	Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. <i>Journal of Neural Transmission Supplementum</i> , 1998 , 53, 223-35		18
41	Stepwise comparative status analysis (STEP): a tool for identification of regional brain syndromes in dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996 , 9, 185-99	3.8	68
40	Decreased lumbar cerebrospinal fluid levels of monoamine metabolites in vascular dementia. <i>International Psychogeriatrics</i> , 1996 , 8, 425-36	3.4	19
39	Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. <i>Journal of Neural Transmission</i> , 1996 , 103, 603-18	4.3	154
38	Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease?. <i>Molecular and Chemical Neuropathology</i> , 1996 , 27, 195-210		75
37	The neurochemistry of Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 1996 , 168, 77-86	3.8	10
36	Detection of cerebrospinal fluid leakage by isoelectric focusing on polyacrylamide gels with silver staining using the PhastSystem. <i>Acta Neurochirurgica</i> , 1995 , 136, 135-9	3	16
35	Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease?. <i>Dementia and Geriatric Cognitive Disorders</i> , 1995 , 6, 306-11	2.6	19
34	Cerebrospinal fluid 'neuronal thread protein' comes from serum by passage over the blood-brain barrier. <i>Experimental Neurology</i> , 1995 , 4, 187-93		14
33	Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. <i>Molecular and Chemical Neuropathology</i> , 1995 , 26, 231-45		619
32	Cerebrospinal Fluid Biochemical Markers in Alzheimer's Disease 1995 , 13-24		
31	Neuron specific enolase in cerebrospinal fluid: a biochemical marker for neuronal degeneration in dementia disorders?. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1994 , 8, 183-91		35
30	Formulas for the quantitation of intrathecal IgG production. Their validity in the presence of blood-brain barrier damage and their utility in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1994 , 121, 90-6	3.2	32
29	Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia. <i>International Psychogeriatrics</i> , 1994 , 6, 13-22; discussion 59-60	3.4	33
28	Neuropeptidergic and Monoaminergic Function in Suicide Victims. <i>Neuropsychopharmacology</i> , 1994 , 11, 265-265	8.7	

27	Low frequency of post-lumbar puncture headache in demented patients. <i>Acta Neurologica Scandinavica</i> , 1993 , 88, 221-3	3.8	51
26	Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age. <i>European Neuropsychopharmacology</i> , 1993 , 3, 55-61	1.2	46
25	Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. <i>European Neurology</i> , 1993 , 33, 129-33	2.1	150
24	Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1993 , 5, 5-15		35
23	Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1992 , 13, 107-13	5.6	42
22	Differences in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging. <i>Aging: Clinical and Experimental Research</i> , 1992 , 4, 301-6		13
21	Subcortical symptoms predominate in vascular dementia. <i>International Journal of Geriatric Psychiatry</i> , 1991 , 6, 137-145	3.9	35
20	Presence of parieto-temporal symptomatology distinguishes early and late onset Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 1991 , 6, 147-154	3.9	42
19	Gangliosides in cerebrospinal fluid in 'probable Alzheimer's disease'. <i>Archives of Neurology</i> , 1991 , 48, 1032-5		64
18	Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. <i>Acta Neurologica Scandinavica</i> , 1990 , 81, 323-6	3.8	127
17	Confusional symptomatology distinguishes early- and late-onset Alzheimer's disease. <i>Aging: Clinical and Experimental Research</i> , 1990 , 2, 395-401		4
16	Intra-blood-brain-barrier synthesis of immunoglobulins in patients with dementia of the Alzheimer type. <i>Alzheimer Disease and Associated Disorders</i> , 1990 , 4, 79-86	2.5	9
15	CSF-Phospho-tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies285-291		7
14	CSF Markers for Early Alzheimer's Disease275-283		
13	Identification of proteins in a human pleural exudate using two-dimensional preparative liquid-phase electrophoresis and matrix-assisted laser desorption/ionization mass spectrometry280-285		
12	Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment		1
11	Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19		1
10	Diagnostic value of plasma neurofilament light: A multicentre validation study		6

9	Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos	1
8	Proteomic blood profiling in mild, severe and critical COVID-19 patients	2
7	Time course of phosphorylated tau181 in blood across the Alzheimer's disease spectrum	2
6	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative	1
5	Plasma glial fibrillary acidic protein is an early marker of A β pathology in Alzheimer's disease	2
4	Liver-specific polygenic risk score is more strongly associated than genome-wide score with Alzheimer's disease diagnosis in a case-control analysis	1
3	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures	2
2	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging,</i>	2
1	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. <i>Multiple Sclerosis Journal</i> ,135245852210972	5 1